<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title></title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft10{font-size:10px;font-family:Times;color:#4291c5;}
	.ft11{font-size:10px;font-family:Times;color:#000000;}
	.ft12{font-size:10px;font-family:Times;color:#000000;}
	.ft13{font-size:17px;font-family:Times;color:#4291c5;}
	.ft14{font-size:13px;font-family:Times;color:#000000;}
	.ft15{font-size:16px;font-family:Times;color:#4291c5;}
	.ft16{font-size:11px;font-family:Times;color:#8dbddc;}
	.ft17{font-size:5px;font-family:Times;color:#4291c5;}
	.ft18{font-size:13px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page1-div" style="position:relative;width:595px;height:918px;">
<img width="595" height="918" src="target001.png" alt="background image"/>
<p style="position:absolute;top:73px;left:536px;white-space:nowrap" class="ft10"><b>19</b></p>
<p style="position:absolute;top:821px;left:90px;white-space:nowrap" class="ft11"><i>An Introduction to Pharmacovigilance</i>, Second Edition. Patrick Waller&#160;</p>
<p style="position:absolute;top:836px;left:90px;white-space:nowrap" class="ft12">and Mira Harrison-Woolrych.&#160;</p>
<p style="position:absolute;top:851px;left:90px;white-space:nowrap" class="ft12">© 2017 John Wiley &amp; Sons Ltd. Published 2017 by John Wiley &amp; Sons Ltd.</p>
<p style="position:absolute;top:223px;left:90px;white-space:nowrap" class="ft13"><b>2</b></p>
<p style="position:absolute;top:322px;left:90px;white-space:nowrap" class="ft14">The two most important concepts in pharmacovigilance are opposites:&#160;</p>
<p style="position:absolute;top:340px;left:90px;white-space:nowrap" class="ft14">harm and safety. The usual term for harm related to a medicine is an&#160;</p>
<p style="position:absolute;top:358px;left:90px;white-space:nowrap" class="ft14">adverse drug reaction (ADR). As pharmacovigilance is fundamentally&#160;</p>
<p style="position:absolute;top:376px;left:90px;white-space:nowrap" class="ft14">about preventing and managing ADRs, this concept is considered first&#160;</p>
<p style="position:absolute;top:394px;left:90px;white-space:nowrap" class="ft14">through&#160;a summary of relevant definitions, classification&#160;systems that&#160;</p>
<p style="position:absolute;top:412px;left:90px;white-space:nowrap" class="ft14">have been proposed, their nature and mechanisms and predisposing&#160;</p>
<p style="position:absolute;top:430px;left:90px;white-space:nowrap" class="ft14">factors. Subsequently, the concept of safety is defined and discussed,&#160;</p>
<p style="position:absolute;top:448px;left:90px;white-space:nowrap" class="ft14">particularly in the context of balancing harms with benefits. Finally,&#160;</p>
<p style="position:absolute;top:466px;left:90px;white-space:nowrap" class="ft14">we consider the issue of causation &#160;how we go about deciding whether&#160;</p>
<p style="position:absolute;top:484px;left:90px;white-space:nowrap" class="ft14">or not a patient has experienced an ADR or whether a medicinal prod-</p>
<p style="position:absolute;top:502px;left:90px;white-space:nowrap" class="ft14">uct really is responsible for an apparent safety problem.</p>
<p style="position:absolute;top:555px;left:90px;white-space:nowrap" class="ft15"><b>&#160;Adverse Drug Reactions</b></p>
<p style="position:absolute;top:596px;left:90px;white-space:nowrap" class="ft16"><b>Definitions</b></p>
<p style="position:absolute;top:622px;left:90px;white-space:nowrap" class="ft14">Standard, internationally&#160;agreed&#160;definitions&#160;of&#160;side&#160;effect,&#160;ADR and&#160;</p>
<p style="position:absolute;top:640px;left:90px;white-space:nowrap" class="ft14">adverse event can be paraphrased as follows:</p>
<p style="position:absolute;top:675px;left:96px;white-space:nowrap" class="ft17">&#160;</p>
<p style="position:absolute;top:675px;left:90px;white-space:nowrap" class="ft17">●</p>
<p style="position:absolute;top:667px;left:103px;white-space:nowrap" class="ft14">A&#160;<i>side effect</i>&#160;is an&#160;<i>unintended effect of a medicine</i>. Normally, it is&#160;</p>
<p style="position:absolute;top:685px;left:103px;white-space:nowrap" class="ft14">undesirable but it could be beneficial (e.g. an anxiolytic effect from&#160;</p>
<p style="position:absolute;top:703px;left:103px;white-space:nowrap" class="ft14">a beta‐blocker prescribed for hypertension).</p>
<p style="position:absolute;top:729px;left:96px;white-space:nowrap" class="ft17">&#160;</p>
<p style="position:absolute;top:729px;left:90px;white-space:nowrap" class="ft17">●</p>
<p style="position:absolute;top:721px;left:103px;white-space:nowrap" class="ft14">An&#160;<i>adverse drug reaction (ADR)</i>&#160;is an&#160;<i>unintended and noxious effect</i>&#160;</p>
<p style="position:absolute;top:739px;left:103px;white-space:nowrap" class="ft14">that is attributable to a medicine when it has been given within the&#160;</p>
<p style="position:absolute;top:757px;left:103px;white-space:nowrap" class="ft14">normal range of doses used in humans.</p>
<p style="position:absolute;top:263px;left:90px;white-space:nowrap" class="ft13"><b>Basic Concepts</b></p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title></title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft20{font-size:10px;font-family:Times;color:#4291c5;}
	.ft21{font-size:10px;font-family:Times;color:#4291c5;}
	.ft22{font-size:5px;font-family:Times;color:#4291c5;}
	.ft23{font-size:13px;font-family:Times;color:#000000;}
	.ft24{font-size:13px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page2-div" style="position:relative;width:595px;height:918px;">
<img width="595" height="918" src="target002.png" alt="background image"/>
<p style="position:absolute;top:73px;left:73px;white-space:nowrap" class="ft20"><i>An Introduction to Pharmacovigilance</i></p>
<p style="position:absolute;top:73px;left:46px;white-space:nowrap" class="ft21"><b>20</b></p>
<p style="position:absolute;top:114px;left:79px;white-space:nowrap" class="ft22">&#160;</p>
<p style="position:absolute;top:114px;left:73px;white-space:nowrap" class="ft22">●</p>
<p style="position:absolute;top:106px;left:87px;white-space:nowrap" class="ft23">An&#160;<i>adverse event (AE)</i>&#160;is an&#160;<i>undesirable occurrence</i>&#160;that occurs in&#160;</p>
<p style="position:absolute;top:124px;left:87px;white-space:nowrap" class="ft23">the&#160;context&#160;of&#160;drug&#160;treatment&#160;but&#160;which&#160;<i>may&#160;or&#160;may&#160;not</i>&#160;be&#160;causally&#160;</p>
<p style="position:absolute;top:142px;left:87px;white-space:nowrap" class="ft23">related to a medicine.</p>
<p style="position:absolute;top:169px;left:86px;white-space:nowrap" class="ft23">The difference between an ADR and an AE is crucial and yet these&#160;</p>
<p style="position:absolute;top:187px;left:73px;white-space:nowrap" class="ft23">terms are widely misused. In practice, determining whether a drug&#160;</p>
<p style="position:absolute;top:205px;left:73px;white-space:nowrap" class="ft23">is &#160;responsible for a particular AE in an&#160;individual&#160;patient is often&#160;</p>
<p style="position:absolute;top:223px;left:73px;white-space:nowrap" class="ft23">&#160;difficult and a judgement has to be made (for an explanation of the&#160;</p>
<p style="position:absolute;top:241px;left:73px;white-space:nowrap" class="ft23">principles on which this judgement is based see Causality Assessment&#160;</p>
<p style="position:absolute;top:259px;left:73px;white-space:nowrap" class="ft23">in Individual Cases). When the judgement is that the drug is a possible&#160;</p>
<p style="position:absolute;top:277px;left:73px;white-space:nowrap" class="ft23">cause, this should be called a&#160;<i>suspected ADR</i>. Reports of such suspi-</p>
<p style="position:absolute;top:295px;left:73px;white-space:nowrap" class="ft23">cions form the basis of spontaneous ADR reporting schemes and the&#160;</p>
<p style="position:absolute;top:313px;left:73px;white-space:nowrap" class="ft23">key point about such data is that they are a&#160;<i>subset</i>&#160;of all the AEs occur-</p>
<p style="position:absolute;top:331px;left:73px;white-space:nowrap" class="ft23">ring during drug treatment which someone (generally a health profes-</p>
<p style="position:absolute;top:349px;left:73px;white-space:nowrap" class="ft23">sional who has seen the patient) has identified as possibly being&#160;</p>
<p style="position:absolute;top:367px;left:73px;white-space:nowrap" class="ft23">drug‐related. It&#160;is the clinician’s experience and&#160;professional&#160;judge-</p>
<p style="position:absolute;top:385px;left:73px;white-space:nowrap" class="ft23">ment that enables him or her to suspect a drug as the cause but, of&#160;</p>
<p style="position:absolute;top:403px;left:73px;white-space:nowrap" class="ft23">course, that suspicion may not be correct.</p>
<p style="position:absolute;top:421px;left:86px;white-space:nowrap" class="ft23">Proper use of the term AE should imply that a more systematic data&#160;</p>
<p style="position:absolute;top:439px;left:73px;white-space:nowrap" class="ft23">collection process has been used so that events will be included,&#160;</p>
<p style="position:absolute;top:457px;left:73px;white-space:nowrap" class="ft23">regardless of whether anyone believes they might be caused by a drug.&#160;</p>
<p style="position:absolute;top:475px;left:73px;white-space:nowrap" class="ft23">In most clinical trials it is a standard practice to document all AEs and&#160;</p>
<p style="position:absolute;top:493px;left:73px;white-space:nowrap" class="ft23">the best way of determining whether a drug is responsible for a par-</p>
<p style="position:absolute;top:511px;left:73px;white-space:nowrap" class="ft23">ticular type of event from such data is by comparison with a control&#160;</p>
<p style="position:absolute;top:529px;left:73px;white-space:nowrap" class="ft23">group. For example, if 10% of patients exposed to an active drug expe-</p>
<p style="position:absolute;top:547px;left:73px;white-space:nowrap" class="ft23">rienced headache compared to 2% on placebo, then this is an estimate&#160;</p>
<p style="position:absolute;top:565px;left:73px;white-space:nowrap" class="ft23">that headache attributable to the drug occurs in 8% (i.e. 10% minus&#160;</p>
<p style="position:absolute;top:583px;left:73px;white-space:nowrap" class="ft23">2%) of patients using it. In such trials it is also common to ask investi-</p>
<p style="position:absolute;top:601px;left:73px;white-space:nowrap" class="ft23">gators whether they believe that individual events are related to the&#160;</p>
<p style="position:absolute;top:619px;left:73px;white-space:nowrap" class="ft23">drug. This is effectively another way of collecting suspected ADRs,&#160;</p>
<p style="position:absolute;top:637px;left:73px;white-space:nowrap" class="ft23">although such data are likely to be more complete if the patient is in a&#160;</p>
<p style="position:absolute;top:655px;left:73px;white-space:nowrap" class="ft23">clinical trial rather than being treated in ordinary practice. It is impor-</p>
<p style="position:absolute;top:673px;left:73px;white-space:nowrap" class="ft23">tant to realise that relying on clinical judgement is a methodologically&#160;</p>
<p style="position:absolute;top:691px;left:73px;white-space:nowrap" class="ft23">weaker approach. Providing that the estimated 8% difference is not&#160;</p>
<p style="position:absolute;top:709px;left:73px;white-space:nowrap" class="ft23">based on very small numbers, then it would be more persuasive evi-</p>
<p style="position:absolute;top:727px;left:73px;white-space:nowrap" class="ft23">dence that the drug causes headache.</p>
<p style="position:absolute;top:745px;left:86px;white-space:nowrap" class="ft23">Thus, the three terms should be applied in the following contexts:</p>
<p style="position:absolute;top:780px;left:79px;white-space:nowrap" class="ft22">&#160;</p>
<p style="position:absolute;top:780px;left:73px;white-space:nowrap" class="ft22">●</p>
<p style="position:absolute;top:772px;left:87px;white-space:nowrap" class="ft23">Use&#160;<i>ADR</i>&#160;to mean that it is now generally accepted that drug x may&#160;</p>
<p style="position:absolute;top:790px;left:87px;white-space:nowrap" class="ft23">cause effect y rather than in relation to individual cases. Qualify the&#160;</p>
<p style="position:absolute;top:808px;left:87px;white-space:nowrap" class="ft23">term with ‘possible’ if there is doubt.</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title></title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft30{font-size:10px;font-family:Times;color:#4291c5;}
	.ft31{font-size:10px;font-family:Times;color:#4291c5;}
	.ft32{font-size:5px;font-family:Times;color:#4291c5;}
	.ft33{font-size:13px;font-family:Times;color:#000000;}
	.ft34{font-size:13px;font-family:Times;color:#000000;}
	.ft35{font-size:11px;font-family:Times;color:#8dbddc;}
	.ft36{font-size:13px;font-family:Times;color:#4291c5;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page3-div" style="position:relative;width:595px;height:918px;">
<img width="595" height="918" src="target003.png" alt="background image"/>
<p style="position:absolute;top:73px;left:451px;white-space:nowrap" class="ft30"><i>Basic Concepts&#160;</i><b>21</b></p>
<p style="position:absolute;top:114px;left:96px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:114px;left:90px;white-space:nowrap" class="ft32">●</p>
<p style="position:absolute;top:106px;left:103px;white-space:nowrap" class="ft33">Use&#160;&#160;<i>suspected ADR</i>&#160;when a health professional or investigator&#160;</p>
<p style="position:absolute;top:124px;left:103px;white-space:nowrap" class="ft33">&#160;indicates that a drug&#160;<i>may</i>&#160;have been responsible for an event in an&#160;</p>
<p style="position:absolute;top:142px;left:103px;white-space:nowrap" class="ft33">individual case. A valid case submitted as a spontaneous report to&#160;</p>
<p style="position:absolute;top:160px;left:103px;white-space:nowrap" class="ft33">a company or regulatory authority (see Chapter 5) is, by definition,&#160;</p>
<p style="position:absolute;top:178px;left:103px;white-space:nowrap" class="ft33">a suspected ADR.</p>
<p style="position:absolute;top:204px;left:96px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:204px;left:90px;white-space:nowrap" class="ft32">●</p>
<p style="position:absolute;top:196px;left:103px;white-space:nowrap" class="ft33">Use&#160;<i>AE</i>&#160;only&#160;in&#160;the&#160;context&#160;of&#160;systematic&#160;data&#160;collection&#160;when&#160;no&#160;</p>
<p style="position:absolute;top:214px;left:103px;white-space:nowrap" class="ft33">element of judgement is involved in determining whether a case is&#160;</p>
<p style="position:absolute;top:232px;left:103px;white-space:nowrap" class="ft33">counted.</p>
<p style="position:absolute;top:279px;left:90px;white-space:nowrap" class="ft35"><b>Classification Systems</b></p>
<p style="position:absolute;top:305px;left:90px;white-space:nowrap" class="ft33">Since the 1970s, ADRs have traditionally been classified into two&#160;</p>
<p style="position:absolute;top:323px;left:90px;white-space:nowrap" class="ft33">broad categories: Types A and B. The usual characteristics of&#160;</p>
<p style="position:absolute;top:341px;left:90px;white-space:nowrap" class="ft33">these different types of reactions are contrasted, followed by some&#160;</p>
<p style="position:absolute;top:359px;left:90px;white-space:nowrap" class="ft33">examples:</p>
<p style="position:absolute;top:388px;left:90px;white-space:nowrap" class="ft36">1)&#160;</p>
<p style="position:absolute;top:388px;left:109px;white-space:nowrap" class="ft34"><i>Type&#160;A</i>&#160;(Augmented) reactions are generally:</p>
<p style="position:absolute;top:414px;left:115px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:414px;left:109px;white-space:nowrap" class="ft32">●</p>
<p style="position:absolute;top:406px;left:122px;white-space:nowrap" class="ft33">Dose‐related</p>
<p style="position:absolute;top:432px;left:115px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:432px;left:109px;white-space:nowrap" class="ft32">●</p>
<p style="position:absolute;top:424px;left:122px;white-space:nowrap" class="ft33">Predictable from drug pharmacology</p>
<p style="position:absolute;top:450px;left:115px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:450px;left:109px;white-space:nowrap" class="ft32">●</p>
<p style="position:absolute;top:442px;left:122px;white-space:nowrap" class="ft33">Common</p>
<p style="position:absolute;top:468px;left:115px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:468px;left:109px;white-space:nowrap" class="ft32">●</p>
<p style="position:absolute;top:460px;left:122px;white-space:nowrap" class="ft33">Reversible</p>
<p style="position:absolute;top:486px;left:115px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:486px;left:109px;white-space:nowrap" class="ft32">●</p>
<p style="position:absolute;top:478px;left:122px;white-space:nowrap" class="ft33">Manageable with dose adjustment.</p>
<p style="position:absolute;top:506px;left:90px;white-space:nowrap" class="ft33">Classic examples of Type A reactions are bleeding with warfarin,&#160;</p>
<p style="position:absolute;top:524px;left:90px;white-space:nowrap" class="ft33">hypoglycaemia with oral anti‐diabetic agents and headache with&#160;</p>
<p style="position:absolute;top:542px;left:90px;white-space:nowrap" class="ft33">nitrates.</p>
<p style="position:absolute;top:571px;left:90px;white-space:nowrap" class="ft36">2)&#160;</p>
<p style="position:absolute;top:571px;left:109px;white-space:nowrap" class="ft34"><i>Type&#160;B</i>&#160;(Bizarre) reactions are generally:</p>
<p style="position:absolute;top:597px;left:115px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:597px;left:109px;white-space:nowrap" class="ft32">●</p>
<p style="position:absolute;top:589px;left:122px;white-space:nowrap" class="ft33">Not dose‐related</p>
<p style="position:absolute;top:615px;left:115px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:615px;left:109px;white-space:nowrap" class="ft32">●</p>
<p style="position:absolute;top:607px;left:122px;white-space:nowrap" class="ft33">Unpredictable</p>
<p style="position:absolute;top:633px;left:115px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:633px;left:109px;white-space:nowrap" class="ft32">●</p>
<p style="position:absolute;top:625px;left:122px;white-space:nowrap" class="ft33">Uncommon</p>
<p style="position:absolute;top:651px;left:115px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:651px;left:109px;white-space:nowrap" class="ft32">●</p>
<p style="position:absolute;top:643px;left:122px;white-space:nowrap" class="ft33">Serious/irreversible</p>
<p style="position:absolute;top:669px;left:115px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:669px;left:109px;white-space:nowrap" class="ft32">●</p>
<p style="position:absolute;top:661px;left:122px;white-space:nowrap" class="ft33">Indicative that the drug needs to be stopped.</p>
<p style="position:absolute;top:689px;left:90px;white-space:nowrap" class="ft33">Classic examples of Type B reactions are anaphylaxis with penicillins,&#160;</p>
<p style="position:absolute;top:707px;left:90px;white-space:nowrap" class="ft33">hepatitis with halothane and agranulocytosis with clozapine.</p>
<p style="position:absolute;top:725px;left:103px;white-space:nowrap" class="ft33">Additional categories of ADRs have also been suggested, as&#160;</p>
<p style="position:absolute;top:743px;left:90px;white-space:nowrap" class="ft33">follows:</p>
<p style="position:absolute;top:780px;left:96px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:780px;left:90px;white-space:nowrap" class="ft32">●</p>
<p style="position:absolute;top:772px;left:103px;white-space:nowrap" class="ft33">Type C (Chronic), e.g. adrenal suppression with corticosteroids.</p>
<p style="position:absolute;top:798px;left:96px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:798px;left:90px;white-space:nowrap" class="ft32">●</p>
<p style="position:absolute;top:790px;left:103px;white-space:nowrap" class="ft33">Type D (Delayed), e.g. tardive dyskinesia with neuroleptics.</p>
<p style="position:absolute;top:816px;left:96px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:816px;left:90px;white-space:nowrap" class="ft32">●</p>
<p style="position:absolute;top:808px;left:103px;white-space:nowrap" class="ft33">Type E (End of use), e.g. withdrawal reactions with benzodiazepines.</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title></title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft40{font-size:10px;font-family:Times;color:#4291c5;}
	.ft41{font-size:10px;font-family:Times;color:#4291c5;}
	.ft42{font-size:11px;font-family:Times;color:#8dbddc;}
	.ft43{font-size:13px;font-family:Times;color:#000000;}
	.ft44{font-size:13px;font-family:Times;color:#000000;}
	.ft45{font-size:11px;font-family:Times;color:#808285;}
	.ft46{font-size:13px;font-family:Times;color:#4291c5;}
	.ft47{font-size:10px;font-family:Times;color:#000000;}
	.ft48{font-size:10px;font-family:Times;color:#000000;}
	.ft49{font-size:10px;line-height:20px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page4-div" style="position:relative;width:595px;height:918px;">
<img width="595" height="918" src="target004.png" alt="background image"/>
<p style="position:absolute;top:73px;left:73px;white-space:nowrap" class="ft40"><i>An Introduction to Pharmacovigilance</i></p>
<p style="position:absolute;top:73px;left:46px;white-space:nowrap" class="ft41"><b>22</b></p>
<p style="position:absolute;top:106px;left:73px;white-space:nowrap" class="ft42"><b>DoTS Classification</b></p>
<p style="position:absolute;top:132px;left:73px;white-space:nowrap" class="ft43">In 2003, a system of classification was proposed by Aronson and&#160;</p>
<p style="position:absolute;top:150px;left:73px;white-space:nowrap" class="ft43">Ferner based on&#160;<i>dose‐relatedness, time course</i>&#160;and&#160;<i>susceptibility;</i>&#160;this is&#160;</p>
<p style="position:absolute;top:168px;left:73px;white-space:nowrap" class="ft43">known as DoTS. The main ways in which ADRs can be classified&#160;</p>
<p style="position:absolute;top:186px;left:73px;white-space:nowrap" class="ft43">within each of these three categories is given in Table 2.1.</p>
<p style="position:absolute;top:204px;left:86px;white-space:nowrap" class="ft43">In terms of dose‐relatedness, ‘toxic’ means that reactions occur as a&#160;</p>
<p style="position:absolute;top:222px;left:73px;white-space:nowrap" class="ft43">result of drug levels being too high, ‘collateral’ means that reactions&#160;</p>
<p style="position:absolute;top:240px;left:73px;white-space:nowrap" class="ft43">occur at drug levels that are in the usual therapeutic range and&#160;</p>
<p style="position:absolute;top:258px;left:73px;white-space:nowrap" class="ft43">‘&#160;hypersusceptibility’&#160;means&#160;that&#160;reactions&#160;can&#160;occur&#160;even&#160;at&#160;very&#160;low,&#160;</p>
<p style="position:absolute;top:276px;left:73px;white-space:nowrap" class="ft43">sub‐therapeutic doses. The terms ‘early’, ‘intermediate’ and ‘late’ have&#160;</p>
<p style="position:absolute;top:294px;left:73px;white-space:nowrap" class="ft43">not been precisely defined; the main difference between ‘late’ and&#160;</p>
<p style="position:absolute;top:312px;left:73px;white-space:nowrap" class="ft43">‘delayed’ reactions&#160;is that&#160;the latter can&#160;occur long&#160;after treatment is&#160;</p>
<p style="position:absolute;top:330px;left:73px;white-space:nowrap" class="ft43">stopped (e.g. cancer, which can occur years after exposure to a causal&#160;</p>
<p style="position:absolute;top:348px;left:73px;white-space:nowrap" class="ft43">agent). A withdrawal reaction means one that is specifically precipi-</p>
<p style="position:absolute;top:366px;left:73px;white-space:nowrap" class="ft43">tated by stopping the drug.</p>
<p style="position:absolute;top:384px;left:86px;white-space:nowrap" class="ft43">If suitable estimates of risk are available, it may be possible to draw&#160;</p>
<p style="position:absolute;top:402px;left:73px;white-space:nowrap" class="ft43">three‐dimensional DoTS diagrams of the probability of an ADR occur-</p>
<p style="position:absolute;top:420px;left:73px;white-space:nowrap" class="ft43">ring in sub‐groups over time and as a function of dose. When this is&#160;</p>
<p style="position:absolute;top:438px;left:73px;white-space:nowrap" class="ft43">not&#160;possible,&#160;qualitative classification may&#160;still&#160;be useful, as shown&#160;by&#160;</p>
<p style="position:absolute;top:456px;left:73px;white-space:nowrap" class="ft43">the following examples.</p>
<p style="position:absolute;top:493px;left:73px;white-space:nowrap" class="ft45"><b>DoTS Classification: Examples</b></p>
<p style="position:absolute;top:510px;left:73px;white-space:nowrap" class="ft46">1)&#160;</p>
<p style="position:absolute;top:510px;left:92px;white-space:nowrap" class="ft44"><i>Osteoporosis&#160;due&#160;to&#160;corticosteroids:</i>&#160;this&#160;reaction&#160;occurs&#160;at&#160;</p>
<p style="position:absolute;top:528px;left:92px;white-space:nowrap" class="ft43">&#160;</p>
<p style="position:absolute;top:528px;left:92px;white-space:nowrap" class="ft43">therapeutic doses, usually after some months of treatment.&#160;</p>
<p style="position:absolute;top:546px;left:92px;white-space:nowrap" class="ft43">Females and older people are at the greatest risk. Hence, it would&#160;</p>
<p style="position:absolute;top:564px;left:92px;white-space:nowrap" class="ft43">be&#160;&#160;classified as:</p>
<p style="position:absolute;top:607px;left:73px;white-space:nowrap" class="ft41"><b>Table 2.1&#160;</b></p>
<p style="position:absolute;top:607px;left:129px;white-space:nowrap" class="ft47">Summary of dose‐relatedness, time course and susceptibility (DoTS)&#160;</p>
<p style="position:absolute;top:622px;left:73px;white-space:nowrap" class="ft47">categories.</p>
<p style="position:absolute;top:660px;left:79px;white-space:nowrap" class="ft48"><b>Dose</b></p>
<p style="position:absolute;top:660px;left:244px;white-space:nowrap" class="ft48"><b>Time</b></p>
<p style="position:absolute;top:660px;left:429px;white-space:nowrap" class="ft48"><b>Susceptibility</b></p>
<p style="position:absolute;top:692px;left:79px;white-space:nowrap" class="ft47">Toxic</p>
<p style="position:absolute;top:692px;left:244px;white-space:nowrap" class="ft47">Independent</p>
<p style="position:absolute;top:692px;left:429px;white-space:nowrap" class="ft47">Age</p>
<p style="position:absolute;top:713px;left:79px;white-space:nowrap" class="ft47">Collateral</p>
<p style="position:absolute;top:713px;left:244px;white-space:nowrap" class="ft47">Dependent:</p>
<p style="position:absolute;top:713px;left:429px;white-space:nowrap" class="ft47">Gender</p>
<p style="position:absolute;top:734px;left:79px;white-space:nowrap" class="ft47">Hypersusceptibility</p>
<p style="position:absolute;top:734px;left:243px;white-space:nowrap" class="ft47">rapid administration</p>
<p style="position:absolute;top:734px;left:429px;white-space:nowrap" class="ft47">Ethnic origin</p>
<p style="position:absolute;top:755px;left:243px;white-space:nowrap" class="ft47">first dose</p>
<p style="position:absolute;top:755px;left:429px;white-space:nowrap" class="ft47">Genetic</p>
<p style="position:absolute;top:776px;left:243px;white-space:nowrap" class="ft47">early, intermediate, late</p>
<p style="position:absolute;top:776px;left:429px;white-space:nowrap" class="ft47">Disease</p>
<p style="position:absolute;top:797px;left:243px;white-space:nowrap" class="ft49">delayed<br/>withdrawal</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title></title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft50{font-size:10px;font-family:Times;color:#4291c5;}
	.ft51{font-size:10px;font-family:Times;color:#4291c5;}
	.ft52{font-size:5px;font-family:Times;color:#4291c5;}
	.ft53{font-size:13px;font-family:Times;color:#000000;}
	.ft54{font-size:13px;font-family:Times;color:#4291c5;}
	.ft55{font-size:13px;font-family:Times;color:#000000;}
	.ft56{font-size:11px;font-family:Times;color:#8dbddc;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page5-div" style="position:relative;width:595px;height:918px;">
<img width="595" height="918" src="target005.png" alt="background image"/>
<p style="position:absolute;top:73px;left:451px;white-space:nowrap" class="ft50"><i>Basic Concepts&#160;</i><b>23</b></p>
<p style="position:absolute;top:114px;left:115px;white-space:nowrap" class="ft52">&#160;</p>
<p style="position:absolute;top:114px;left:109px;white-space:nowrap" class="ft52">●</p>
<p style="position:absolute;top:106px;left:122px;white-space:nowrap" class="ft53">Dose: collateral effect</p>
<p style="position:absolute;top:132px;left:115px;white-space:nowrap" class="ft52">&#160;</p>
<p style="position:absolute;top:132px;left:109px;white-space:nowrap" class="ft52">●</p>
<p style="position:absolute;top:124px;left:122px;white-space:nowrap" class="ft53">Time: late</p>
<p style="position:absolute;top:150px;left:115px;white-space:nowrap" class="ft52">&#160;</p>
<p style="position:absolute;top:150px;left:109px;white-space:nowrap" class="ft52">●</p>
<p style="position:absolute;top:142px;left:122px;white-space:nowrap" class="ft53">Susceptibility: age, sex.</p>
<p style="position:absolute;top:169px;left:90px;white-space:nowrap" class="ft54">2)&#160;</p>
<p style="position:absolute;top:169px;left:109px;white-space:nowrap" class="ft55"><i>Anaphylaxis due to penicillin:</i>&#160;this reaction can occur with very&#160;</p>
<p style="position:absolute;top:187px;left:109px;white-space:nowrap" class="ft53">small doses and within minutes of taking the first dose of a course,&#160;</p>
<p style="position:absolute;top:205px;left:109px;white-space:nowrap" class="ft53">but true anaphylaxis only occurs when the drug (or a closely related&#160;</p>
<p style="position:absolute;top:223px;left:109px;white-space:nowrap" class="ft53">agent) has been used previously. Hence, it would be classified as:</p>
<p style="position:absolute;top:249px;left:115px;white-space:nowrap" class="ft52">&#160;</p>
<p style="position:absolute;top:249px;left:109px;white-space:nowrap" class="ft52">●</p>
<p style="position:absolute;top:241px;left:122px;white-space:nowrap" class="ft53">Dose: hypersusceptibility</p>
<p style="position:absolute;top:267px;left:115px;white-space:nowrap" class="ft52">&#160;</p>
<p style="position:absolute;top:267px;left:109px;white-space:nowrap" class="ft52">●</p>
<p style="position:absolute;top:259px;left:122px;white-space:nowrap" class="ft53">Time: first dose</p>
<p style="position:absolute;top:285px;left:115px;white-space:nowrap" class="ft52">&#160;</p>
<p style="position:absolute;top:285px;left:109px;white-space:nowrap" class="ft52">●</p>
<p style="position:absolute;top:277px;left:122px;white-space:nowrap" class="ft53">Susceptibility: requires previous sensitisation.</p>
<p style="position:absolute;top:302px;left:103px;white-space:nowrap" class="ft53">The DoTS approach is useful because it addresses the limitations of&#160;</p>
<p style="position:absolute;top:320px;left:90px;white-space:nowrap" class="ft53">the Type A/B scheme into which many ADRs do not clearly fit and in&#160;</p>
<p style="position:absolute;top:338px;left:90px;white-space:nowrap" class="ft53">providing pointers as to how specific ADRs can be avoided.</p>
<p style="position:absolute;top:378px;left:90px;white-space:nowrap" class="ft56"><b>Nature and Mechanisms of ADRs</b></p>
<p style="position:absolute;top:404px;left:90px;white-space:nowrap" class="ft53">The adverse effects of medicines usually mimic diseases or syndromes&#160;</p>
<p style="position:absolute;top:422px;left:90px;white-space:nowrap" class="ft53">that occur naturally and have a variety of non‐drug potential causes&#160;</p>
<p style="position:absolute;top:440px;left:90px;white-space:nowrap" class="ft53">(e.g. hepatitis or aplastic anaemia). As a general rule, considering&#160;</p>
<p style="position:absolute;top:458px;left:90px;white-space:nowrap" class="ft53">other potential causes is an important part of the assessment of a&#160;</p>
<p style="position:absolute;top:476px;left:90px;white-space:nowrap" class="ft53">potential adverse effect (see Causality Assessment). However, there&#160;</p>
<p style="position:absolute;top:494px;left:90px;white-space:nowrap" class="ft53">are a few unique syndromes that, as far as we yet know, seem to be&#160;</p>
<p style="position:absolute;top:512px;left:90px;white-space:nowrap" class="ft53">caused only by specific drugs. Four examples of this are:</p>
<p style="position:absolute;top:538px;left:90px;white-space:nowrap" class="ft54">1)&#160;</p>
<p style="position:absolute;top:538px;left:109px;white-space:nowrap" class="ft53">Vaginal cancer in young women caused by maternal exposure to&#160;</p>
<p style="position:absolute;top:556px;left:109px;white-space:nowrap" class="ft53">diethylstilboestrol</p>
<p style="position:absolute;top:574px;left:90px;white-space:nowrap" class="ft54">2)&#160;</p>
<p style="position:absolute;top:574px;left:109px;white-space:nowrap" class="ft53">Oculomucocutaneous syndrome caused by practolol (see Chapter 1)</p>
<p style="position:absolute;top:592px;left:90px;white-space:nowrap" class="ft54">3)&#160;</p>
<p style="position:absolute;top:592px;left:109px;white-space:nowrap" class="ft53">Eosinophilia‐myalgia syndrome caused by some&#160;l‐tryptophan&#160;</p>
<p style="position:absolute;top:610px;left:109px;white-space:nowrap" class="ft53">products</p>
<p style="position:absolute;top:628px;left:90px;white-space:nowrap" class="ft54">4)&#160;</p>
<p style="position:absolute;top:628px;left:109px;white-space:nowrap" class="ft53">Fibrosing colonopathy induced by large doses of high‐strength&#160;</p>
<p style="position:absolute;top:646px;left:109px;white-space:nowrap" class="ft53">pancreatic enzymes in children with cystic fibrosis.</p>
<p style="position:absolute;top:673px;left:103px;white-space:nowrap" class="ft53">In broad terms, there are at least four mechanisms for ADRs:</p>
<p style="position:absolute;top:698px;left:90px;white-space:nowrap" class="ft54">1)&#160;</p>
<p style="position:absolute;top:698px;left:109px;white-space:nowrap" class="ft53">Exaggerated therapeutic response at the target site (e.g. bleeding&#160;</p>
<p style="position:absolute;top:716px;left:109px;white-space:nowrap" class="ft53">with warfarin)</p>
<p style="position:absolute;top:734px;left:90px;white-space:nowrap" class="ft54">2)&#160;</p>
<p style="position:absolute;top:734px;left:109px;white-space:nowrap" class="ft53">Desired&#160;pharmacological&#160;effect&#160;at&#160;another&#160;site&#160;(e.g.&#160;headache&#160;with&#160;</p>
<p style="position:absolute;top:752px;left:109px;white-space:nowrap" class="ft53">glyceryltrinitrate)</p>
<p style="position:absolute;top:770px;left:90px;white-space:nowrap" class="ft54">3)&#160;</p>
<p style="position:absolute;top:770px;left:109px;white-space:nowrap" class="ft53">Additional (secondary) pharmacological actions (e.g. prolongation&#160;</p>
<p style="position:absolute;top:788px;left:109px;white-space:nowrap" class="ft53">of the QT interval on the electrocardiogram – many drugs)</p>
<p style="position:absolute;top:806px;left:90px;white-space:nowrap" class="ft54">4)&#160;</p>
<p style="position:absolute;top:806px;left:109px;white-space:nowrap" class="ft53">Triggering an immunological response (e.g. anaphylaxis due to&#160;</p>
<p style="position:absolute;top:824px;left:109px;white-space:nowrap" class="ft53">many drugs).</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title></title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft60{font-size:10px;font-family:Times;color:#4291c5;}
	.ft61{font-size:10px;font-family:Times;color:#4291c5;}
	.ft62{font-size:13px;font-family:Times;color:#000000;}
	.ft63{font-size:11px;font-family:Times;color:#8dbddc;}
	.ft64{font-size:5px;font-family:Times;color:#4291c5;}
	.ft65{font-size:13px;font-family:Times;color:#000000;}
	.ft66{font-size:8px;font-family:Times;color:#000000;}
	.ft67{font-size:6px;font-family:Times;color:#000000;}
	.ft68{font-size:10px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page6-div" style="position:relative;width:595px;height:918px;">
<img width="595" height="918" src="target006.png" alt="background image"/>
<p style="position:absolute;top:73px;left:73px;white-space:nowrap" class="ft60"><i>An Introduction to Pharmacovigilance</i></p>
<p style="position:absolute;top:73px;left:46px;white-space:nowrap" class="ft61"><b>24</b></p>
<p style="position:absolute;top:106px;left:86px;white-space:nowrap" class="ft62">Particularly at the time they are first identified, the mechanism&#160;</p>
<p style="position:absolute;top:124px;left:73px;white-space:nowrap" class="ft62">of many ADRs is unknown or incompletely understood. Some have&#160;</p>
<p style="position:absolute;top:142px;left:73px;white-space:nowrap" class="ft62">a pharmacokinetic basis e.g. impaired hepatic metabolism due to a&#160;</p>
<p style="position:absolute;top:160px;left:73px;white-space:nowrap" class="ft62">genetic polymorphism or the effect of another medication taken con-</p>
<p style="position:absolute;top:178px;left:73px;white-space:nowrap" class="ft62">currently, leading to increased plasma concentrations. Understanding&#160;</p>
<p style="position:absolute;top:196px;left:73px;white-space:nowrap" class="ft62">genetic predispositions is likely to be an important factor in determin-</p>
<p style="position:absolute;top:214px;left:73px;white-space:nowrap" class="ft62">ing how we might prevent ADRs in the future (see Chapter 9).</p>
<p style="position:absolute;top:246px;left:73px;white-space:nowrap" class="ft63"><b>Predisposing Factors for ADRs</b></p>
<p style="position:absolute;top:272px;left:73px;white-space:nowrap" class="ft62">The&#160;main clinical factors&#160;that increase&#160;the&#160;chance that&#160;patients will&#160;</p>
<p style="position:absolute;top:290px;left:73px;white-space:nowrap" class="ft62">experience an adverse reaction are as follows:</p>
<p style="position:absolute;top:325px;left:79px;white-space:nowrap" class="ft64">&#160;</p>
<p style="position:absolute;top:325px;left:73px;white-space:nowrap" class="ft64">●</p>
<p style="position:absolute;top:317px;left:87px;white-space:nowrap" class="ft65"><i>Age</i> – the elderly and neonates are at greatest risk.</p>
<p style="position:absolute;top:343px;left:79px;white-space:nowrap" class="ft64">&#160;</p>
<p style="position:absolute;top:343px;left:73px;white-space:nowrap" class="ft64">●</p>
<p style="position:absolute;top:335px;left:87px;white-space:nowrap" class="ft65"><i>Gender</i> – women are generally at higher risk.</p>
<p style="position:absolute;top:361px;left:79px;white-space:nowrap" class="ft64">&#160;</p>
<p style="position:absolute;top:361px;left:73px;white-space:nowrap" class="ft64">●</p>
<p style="position:absolute;top:353px;left:87px;white-space:nowrap" class="ft65"><i>Ethnic origin</i> &#160;– &#160;can affect drug metabolism because of genetic&#160;</p>
<p style="position:absolute;top:371px;left:87px;white-space:nowrap" class="ft62">predisposition.</p>
<p style="position:absolute;top:397px;left:79px;white-space:nowrap" class="ft64">&#160;</p>
<p style="position:absolute;top:397px;left:73px;white-space:nowrap" class="ft64">●</p>
<p style="position:absolute;top:389px;left:87px;white-space:nowrap" class="ft65"><i>Impaired excretory mechanisms</i> &#160;– &#160;reduced hepatic and/or renal&#160;</p>
<p style="position:absolute;top:407px;left:87px;white-space:nowrap" class="ft62">function.</p>
<p style="position:absolute;top:433px;left:79px;white-space:nowrap" class="ft64">&#160;</p>
<p style="position:absolute;top:433px;left:73px;white-space:nowrap" class="ft64">●</p>
<p style="position:absolute;top:425px;left:87px;white-space:nowrap" class="ft65"><i>Specific diseases</i> – e.g. asthma and beta‐blockers</p>
<p style="position:absolute;top:423px;left:388px;white-space:nowrap" class="ft66">1</p>
<p style="position:absolute;top:425px;left:394px;white-space:nowrap" class="ft62">.</p>
<p style="position:absolute;top:451px;left:79px;white-space:nowrap" class="ft64">&#160;</p>
<p style="position:absolute;top:451px;left:73px;white-space:nowrap" class="ft64">●</p>
<p style="position:absolute;top:443px;left:87px;white-space:nowrap" class="ft65"><i>Polypharmacy</i>&#160;–use of multiple drugs simultaneously, increasing&#160;</p>
<p style="position:absolute;top:461px;left:87px;white-space:nowrap" class="ft62">the potential for drug interactions (see next section).</p>
<p style="position:absolute;top:487px;left:79px;white-space:nowrap" class="ft64">&#160;</p>
<p style="position:absolute;top:487px;left:73px;white-space:nowrap" class="ft64">●</p>
<p style="position:absolute;top:479px;left:87px;white-space:nowrap" class="ft65"><i>Any previous history of an ADR</i>.</p>
<p style="position:absolute;top:513px;left:73px;white-space:nowrap" class="ft63"><b>Drug Interactions</b></p>
<p style="position:absolute;top:539px;left:73px;white-space:nowrap" class="ft62">Drug interactions occur when the presence of one drug affects the&#160;</p>
<p style="position:absolute;top:557px;left:73px;white-space:nowrap" class="ft62">activity of another. This occurs either because both drugs act through&#160;</p>
<p style="position:absolute;top:575px;left:73px;white-space:nowrap" class="ft62">the same pathway(s) &#160;– &#160;these are called&#160;<i>pharmacodynamic</i>&#160;interac-</p>
<p style="position:absolute;top:593px;left:73px;white-space:nowrap" class="ft62">tions – or through effects on absorption, distribution, metabolism or&#160;</p>
<p style="position:absolute;top:611px;left:73px;white-space:nowrap" class="ft62">excretion &#160;– &#160;<i>pharmacokinetic</i>&#160;interactions. The&#160;result&#160;may&#160;be an&#160;</p>
<p style="position:absolute;top:629px;left:73px;white-space:nowrap" class="ft62">adverse reaction or modified effectiveness. Some specific examples&#160;</p>
<p style="position:absolute;top:647px;left:73px;white-space:nowrap" class="ft62">are given as follows:</p>
<p style="position:absolute;top:682px;left:79px;white-space:nowrap" class="ft64">&#160;</p>
<p style="position:absolute;top:682px;left:73px;white-space:nowrap" class="ft64">●</p>
<p style="position:absolute;top:674px;left:87px;white-space:nowrap" class="ft65"><i>Pharmacodynamic</i> &#160;– &#160;concomitant use of two drugs with similar&#160;</p>
<p style="position:absolute;top:692px;left:87px;white-space:nowrap" class="ft62">effects. For example, an angiotensin converting enzyme (ACE)&#160;</p>
<p style="position:absolute;top:710px;left:87px;white-space:nowrap" class="ft62">inhibitor plus a potassium‐sparing diuretic can result in hyper-</p>
<p style="position:absolute;top:728px;left:87px;white-space:nowrap" class="ft62">kalaemia and cardiac arrhythmias.</p>
<p style="position:absolute;top:764px;left:73px;white-space:nowrap" class="ft67">1</p>
<p style="position:absolute;top:766px;left:77px;white-space:nowrap" class="ft68">&#160;&#160;This is a very important example because the effect of beta‐blockers in patients with&#160;</p>
<p style="position:absolute;top:781px;left:73px;white-space:nowrap" class="ft68">asthma is to constrict the airways and to counteract some of the treatments that the&#160;</p>
<p style="position:absolute;top:796px;left:73px;white-space:nowrap" class="ft68">patient may be taking (e.g. beta‐agonists). Giving a beta‐blocker to an asthmatic patient&#160;</p>
<p style="position:absolute;top:811px;left:73px;white-space:nowrap" class="ft68">can prove to be fatal.</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title></title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft70{font-size:10px;font-family:Times;color:#4291c5;}
	.ft71{font-size:10px;font-family:Times;color:#4291c5;}
	.ft72{font-size:5px;font-family:Times;color:#4291c5;}
	.ft73{font-size:13px;font-family:Times;color:#000000;}
	.ft74{font-size:13px;font-family:Times;color:#000000;}
	.ft75{font-size:16px;font-family:Times;color:#4291c5;}
	.ft76{font-size:11px;font-family:Times;color:#8dbddc;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page7-div" style="position:relative;width:595px;height:918px;">
<img width="595" height="918" src="target007.png" alt="background image"/>
<p style="position:absolute;top:73px;left:451px;white-space:nowrap" class="ft70"><i>Basic Concepts&#160;</i><b>25</b></p>
<p style="position:absolute;top:114px;left:96px;white-space:nowrap" class="ft72">&#160;</p>
<p style="position:absolute;top:114px;left:90px;white-space:nowrap" class="ft72">●</p>
<p style="position:absolute;top:106px;left:103px;white-space:nowrap" class="ft73"><i>Absorption</i> &#160;– &#160;orlistat, a drug used to treat obesity, impairs the&#160;</p>
<p style="position:absolute;top:124px;left:103px;white-space:nowrap" class="ft74">absorption of some medicines (e.g. anticonvulsants) and its use in&#160;</p>
<p style="position:absolute;top:142px;left:103px;white-space:nowrap" class="ft74">this context could lead to convulsions.</p>
<p style="position:absolute;top:168px;left:96px;white-space:nowrap" class="ft72">&#160;</p>
<p style="position:absolute;top:168px;left:90px;white-space:nowrap" class="ft72">●</p>
<p style="position:absolute;top:160px;left:103px;white-space:nowrap" class="ft73"><i>Distribution</i> &#160;– &#160;protein‐bound drugs (e.g. phenytoin, aspirin) can&#160;</p>
<p style="position:absolute;top:178px;left:103px;white-space:nowrap" class="ft74">displace each other, resulting in an increased unbound (i.e. active)&#160;</p>
<p style="position:absolute;top:196px;left:103px;white-space:nowrap" class="ft74">fraction of drug in plasma.</p>
<p style="position:absolute;top:222px;left:96px;white-space:nowrap" class="ft72">&#160;</p>
<p style="position:absolute;top:222px;left:90px;white-space:nowrap" class="ft72">●</p>
<p style="position:absolute;top:214px;left:103px;white-space:nowrap" class="ft73"><i>Metabolism</i> &#160;– &#160;many medicines (e.g. cimetidine and omeprazole),&#160;</p>
<p style="position:absolute;top:232px;left:103px;white-space:nowrap" class="ft74">drugs that reduce gastric acid by different mechanisms, inhibit the&#160;</p>
<p style="position:absolute;top:250px;left:103px;white-space:nowrap" class="ft74">metabolism of warfarin and thereby increase its anticoagulant&#160;</p>
<p style="position:absolute;top:268px;left:103px;white-space:nowrap" class="ft74">effect, leading to bleeding reactions.</p>
<p style="position:absolute;top:294px;left:96px;white-space:nowrap" class="ft72">&#160;</p>
<p style="position:absolute;top:294px;left:90px;white-space:nowrap" class="ft72">●</p>
<p style="position:absolute;top:286px;left:103px;white-space:nowrap" class="ft73"><i>Excretion</i> – amiodarone, an anti‐arrhythmic drug, reduces excre-</p>
<p style="position:absolute;top:304px;left:103px;white-space:nowrap" class="ft74">tion of, and therefore the dosage requirements for, digoxin – a drug&#160;</p>
<p style="position:absolute;top:322px;left:103px;white-space:nowrap" class="ft74">widely prescribed to patients with cardiac disease.</p>
<p style="position:absolute;top:349px;left:103px;white-space:nowrap" class="ft74">Many drugs are metabolised by hepatic cytochrome P450 (CYP450)&#160;</p>
<p style="position:absolute;top:367px;left:90px;white-space:nowrap" class="ft74">enzymes, the activity of which may be induced or inhibited by a wide&#160;</p>
<p style="position:absolute;top:385px;left:90px;white-space:nowrap" class="ft74">variety of drugs. There are several subgroups of CYP450 enzymes and&#160;</p>
<p style="position:absolute;top:403px;left:90px;white-space:nowrap" class="ft74">their activity can also be affected by:</p>
<p style="position:absolute;top:438px;left:96px;white-space:nowrap" class="ft72">&#160;</p>
<p style="position:absolute;top:438px;left:90px;white-space:nowrap" class="ft72">●</p>
<p style="position:absolute;top:430px;left:103px;white-space:nowrap" class="ft73"><i>Herbal medicines</i> – e.g. St John’s wort is an enzyme inducer and can&#160;</p>
<p style="position:absolute;top:448px;left:103px;white-space:nowrap" class="ft74">reduce the effectiveness of various drugs including ciclosporin.</p>
<p style="position:absolute;top:474px;left:96px;white-space:nowrap" class="ft72">&#160;</p>
<p style="position:absolute;top:474px;left:90px;white-space:nowrap" class="ft72">●</p>
<p style="position:absolute;top:466px;left:103px;white-space:nowrap" class="ft73"><i>Dietary products</i> – e.g. grapefruit juice is an enzyme inhibitor and&#160;</p>
<p style="position:absolute;top:484px;left:103px;white-space:nowrap" class="ft74">increases plasma concentrations of some calcium channel blockers,&#160;</p>
<p style="position:absolute;top:502px;left:103px;white-space:nowrap" class="ft74">drugs that are used to treat hypertension and angina.</p>
<p style="position:absolute;top:529px;left:103px;white-space:nowrap" class="ft74">Drugs&#160;can&#160;also&#160;interact&#160;with&#160;<i>alcohol</i> – for&#160;example,&#160;metronidazole&#160;</p>
<p style="position:absolute;top:547px;left:90px;white-space:nowrap" class="ft74">(an antibiotic) blocks part of the metabolic pathway for alcohol&#160;</p>
<p style="position:absolute;top:565px;left:90px;white-space:nowrap" class="ft74">and &#160;concomitant use, which is not recommended, leads to intense&#160;</p>
<p style="position:absolute;top:583px;left:90px;white-space:nowrap" class="ft74">vasodilatation.</p>
<p style="position:absolute;top:633px;left:90px;white-space:nowrap" class="ft75"><b>&#160;The Concept of Safety</b></p>
<p style="position:absolute;top:674px;left:90px;white-space:nowrap" class="ft76"><b>Definition</b></p>
<p style="position:absolute;top:700px;left:90px;white-space:nowrap" class="ft74">Safety&#160;can be defined as&#160;<i>relative absence of harm.</i>&#160;When using&#160;the&#160;</p>
<p style="position:absolute;top:718px;left:90px;white-space:nowrap" class="ft74">word&#160;‘safety’&#160;we&#160;often&#160;mean&#160;something&#160;else.&#160;For&#160;example,&#160;safety&#160;data&#160;</p>
<p style="position:absolute;top:736px;left:90px;white-space:nowrap" class="ft74">often&#160;means&#160;collection&#160;of&#160;reports&#160;of&#160;harm.&#160;Safety&#160;departments&#160;in&#160;the&#160;</p>
<p style="position:absolute;top:754px;left:90px;white-space:nowrap" class="ft74">pharmaceutical industry are generally focused much more on harm&#160;</p>
<p style="position:absolute;top:772px;left:90px;white-space:nowrap" class="ft74">than safety. And yet how safe something is a key question for the user&#160;</p>
<p style="position:absolute;top:790px;left:90px;white-space:nowrap" class="ft74">and one that pharmacovigilance is gradually becoming more targeted&#160;</p>
<p style="position:absolute;top:808px;left:90px;white-space:nowrap" class="ft74">at. To establish safety, it is not enough to sit around and hope that&#160;</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title></title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft80{font-size:10px;font-family:Times;color:#4291c5;}
	.ft81{font-size:10px;font-family:Times;color:#4291c5;}
	.ft82{font-size:13px;font-family:Times;color:#000000;}
	.ft83{font-size:13px;font-family:Times;color:#000000;}
	.ft84{font-size:11px;font-family:Times;color:#8dbddc;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page8-div" style="position:relative;width:595px;height:918px;">
<img width="595" height="918" src="target008.png" alt="background image"/>
<p style="position:absolute;top:73px;left:73px;white-space:nowrap" class="ft80"><i>An Introduction to Pharmacovigilance</i></p>
<p style="position:absolute;top:73px;left:46px;white-space:nowrap" class="ft81"><b>26</b></p>
<p style="position:absolute;top:106px;left:73px;white-space:nowrap" class="ft82">nothing much happens. Active processes are required to generate data&#160;</p>
<p style="position:absolute;top:124px;left:73px;white-space:nowrap" class="ft82">in&#160;large&#160;numbers&#160;of&#160;users – this&#160;is&#160;one&#160;of&#160;the&#160;main&#160;challenges&#160;facing&#160;</p>
<p style="position:absolute;top:142px;left:73px;white-space:nowrap" class="ft82">people working in the field.</p>
<p style="position:absolute;top:160px;left:86px;white-space:nowrap" class="ft82">In practice, there is no such thing as absolute safety because, even if&#160;</p>
<p style="position:absolute;top:178px;left:73px;white-space:nowrap" class="ft82">something is completely harmless, it is impossible to demonstrate that&#160;</p>
<p style="position:absolute;top:196px;left:73px;white-space:nowrap" class="ft82">with complete certainty. For example, if a drug were given to 999&#160;999&#160;</p>
<p style="position:absolute;top:214px;left:73px;white-space:nowrap" class="ft82">people without any problem occurring, it would be very unlikely that&#160;</p>
<p style="position:absolute;top:232px;left:73px;white-space:nowrap" class="ft82">the millionth person to use it would be harmed, but it is not impossi-</p>
<p style="position:absolute;top:250px;left:73px;white-space:nowrap" class="ft82">ble. In any case, we know that all pharmacologically active substances&#160;</p>
<p style="position:absolute;top:268px;left:73px;white-space:nowrap" class="ft82">have&#160;the&#160;potential&#160;to&#160;cause&#160;harm.&#160;When&#160;we&#160;say&#160;that&#160;a&#160;drug&#160;is&#160;‘safe’,&#160;we&#160;</p>
<p style="position:absolute;top:286px;left:73px;white-space:nowrap" class="ft82">mean that there is a low probability of harm which,&#160;<i>in the context of&#160;</i></p>
<p style="position:absolute;top:304px;left:73px;white-space:nowrap" class="ft83"><i>the disease being treated and the expected benefits of the drug</i>, can be&#160;</p>
<p style="position:absolute;top:322px;left:73px;white-space:nowrap" class="ft82">considered acceptable. Disease context is important because patients&#160;</p>
<p style="position:absolute;top:340px;left:73px;white-space:nowrap" class="ft82">with more serious illnesses are much more likely to be prepared to&#160;</p>
<p style="position:absolute;top:358px;left:73px;white-space:nowrap" class="ft82">accept potentially harmful treatments than those who have minor or&#160;</p>
<p style="position:absolute;top:376px;left:73px;white-space:nowrap" class="ft82">self‐limiting illnesses. ‘Acceptability’ is a subjective judgement which&#160;</p>
<p style="position:absolute;top:394px;left:73px;white-space:nowrap" class="ft82">ultimately is made by comparing both the positive and the negative&#160;</p>
<p style="position:absolute;top:412px;left:73px;white-space:nowrap" class="ft82">consequences of one course of action (e.g. a drug) with another (which&#160;</p>
<p style="position:absolute;top:430px;left:73px;white-space:nowrap" class="ft82">could be any form of treatment or no treatment). We will return to&#160;</p>
<p style="position:absolute;top:448px;left:73px;white-space:nowrap" class="ft82">this point in more detail in the section on risk–benefit balance.</p>
<p style="position:absolute;top:466px;left:86px;white-space:nowrap" class="ft82">Safety is a moving ball – there is a need to re‐evaluate it as experience&#160;</p>
<p style="position:absolute;top:484px;left:73px;white-space:nowrap" class="ft82">accumulates. Treatments previously considered acceptably&#160;safe may&#160;</p>
<p style="position:absolute;top:502px;left:73px;white-space:nowrap" class="ft82">become ‘unsafe’ in the light of new evidence or the discovery of safer&#160;</p>
<p style="position:absolute;top:520px;left:73px;white-space:nowrap" class="ft82">alternatives. An example of the latter was the antihistamine terfena-</p>
<p style="position:absolute;top:538px;left:73px;white-space:nowrap" class="ft82">dine which was widely used in the treatment of hay fever until the early&#160;</p>
<p style="position:absolute;top:556px;left:73px;white-space:nowrap" class="ft82">1990s. It was then discovered that it could, very rarely, cause serious or&#160;</p>
<p style="position:absolute;top:574px;left:73px;white-space:nowrap" class="ft82">fatal ventricular arrhythmias through the mechanism of prolonging&#160;</p>
<p style="position:absolute;top:592px;left:73px;white-space:nowrap" class="ft82">the QT interval. Terfenadine is a pro‐drug (i.e. precursor of the active&#160;</p>
<p style="position:absolute;top:610px;left:73px;white-space:nowrap" class="ft82">substance) which is normally completely metabolised on the first‐pass&#160;</p>
<p style="position:absolute;top:628px;left:73px;white-space:nowrap" class="ft82">through the liver. It is the parent drug terfenadine that prolongs the QT&#160;</p>
<p style="position:absolute;top:646px;left:73px;white-space:nowrap" class="ft82">interval (when its metabolism is inhibited) but the metabolite is&#160;</p>
<p style="position:absolute;top:664px;left:73px;white-space:nowrap" class="ft82">responsible for the beneficial effects. Thus, the metabolite, known as&#160;</p>
<p style="position:absolute;top:682px;left:73px;white-space:nowrap" class="ft82">fexofenadine, was developed for this indication and rapidly accepted to&#160;</p>
<p style="position:absolute;top:700px;left:73px;white-space:nowrap" class="ft82">be a safer alternative, following which terfenadine became obsolete.</p>
<p style="position:absolute;top:744px;left:73px;white-space:nowrap" class="ft84"><b>Measuring Risk</b></p>
<p style="position:absolute;top:770px;left:73px;white-space:nowrap" class="ft82">To assess how safe something is we need to identify and measure the&#160;</p>
<p style="position:absolute;top:788px;left:73px;white-space:nowrap" class="ft82">risks of harm associated with it.&#160;<i>Risk</i>&#160;is the probability of an adverse&#160;</p>
<p style="position:absolute;top:806px;left:73px;white-space:nowrap" class="ft82">outcome. It may be expressed in the following terms:</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title></title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft90{font-size:10px;font-family:Times;color:#4291c5;}
	.ft91{font-size:10px;font-family:Times;color:#4291c5;}
	.ft92{font-size:5px;font-family:Times;color:#4291c5;}
	.ft93{font-size:13px;font-family:Times;color:#000000;}
	.ft94{font-size:13px;font-family:Times;color:#000000;}
	.ft95{font-size:13px;font-family:Times;color:#000000;}
	.ft96{font-size:10px;font-family:Times;color:#000000;}
	.ft97{font-size:10px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page9-div" style="position:relative;width:595px;height:918px;">
<img width="595" height="918" src="target009.png" alt="background image"/>
<p style="position:absolute;top:73px;left:451px;white-space:nowrap" class="ft90"><i>Basic Concepts&#160;</i><b>27</b></p>
<p style="position:absolute;top:114px;left:96px;white-space:nowrap" class="ft92">&#160;</p>
<p style="position:absolute;top:114px;left:90px;white-space:nowrap" class="ft92">●</p>
<p style="position:absolute;top:106px;left:103px;white-space:nowrap" class="ft93"><i>Absolute risk</i>&#160;&#160;<b>–</b>&#160;an absolute risk must have a numerator and a&#160;</p>
<p style="position:absolute;top:124px;left:103px;white-space:nowrap" class="ft94">denominator but it may be a proportion (e.g. 1 in 100) or a rate&#160;</p>
<p style="position:absolute;top:142px;left:103px;white-space:nowrap" class="ft94">which includes time (e.g. 1 in 100 per year). The null value (i.e. no&#160;</p>
<p style="position:absolute;top:160px;left:103px;white-space:nowrap" class="ft94">increased risk) is zero.</p>
<p style="position:absolute;top:186px;left:96px;white-space:nowrap" class="ft92">&#160;</p>
<p style="position:absolute;top:186px;left:90px;white-space:nowrap" class="ft92">●</p>
<p style="position:absolute;top:178px;left:103px;white-space:nowrap" class="ft93"><i>Relative&#160;risk</i>&#160;<b>–</b>&#160;a relative&#160;risk&#160;is&#160;a ratio&#160;and&#160;makes comparison&#160;with&#160;a&#160;</p>
<p style="position:absolute;top:196px;left:103px;white-space:nowrap" class="ft94">specified alternative (e.g. a twofold increase compared to no treat-</p>
<p style="position:absolute;top:214px;left:103px;white-space:nowrap" class="ft94">ment is a relative risk of 2). The null value is one.</p>
<p style="position:absolute;top:241px;left:103px;white-space:nowrap" class="ft94">Absolute risk provides more useful information than relative risk&#160;</p>
<p style="position:absolute;top:259px;left:90px;white-space:nowrap" class="ft94">but&#160;the&#160;latter&#160;is&#160;often&#160;easier&#160;to&#160;measure.&#160;Interpreting&#160;a&#160;relative&#160;risk&#160;is&#160;</p>
<p style="position:absolute;top:277px;left:90px;white-space:nowrap" class="ft94">difficult without knowledge of the&#160;<i>baseline</i>&#160;rate (i.e. the background&#160;</p>
<p style="position:absolute;top:295px;left:90px;white-space:nowrap" class="ft94">probability&#160;of&#160;the&#160;effect&#160;occurring&#160;in&#160;the&#160;absence&#160;of&#160;any&#160;intervention).&#160;</p>
<p style="position:absolute;top:313px;left:90px;white-space:nowrap" class="ft94">Several times a very small number is still a small number, whereas a&#160;</p>
<p style="position:absolute;top:331px;left:90px;white-space:nowrap" class="ft94">small&#160;increase&#160;in the&#160;relative&#160;risk&#160;of something&#160;common&#160;could be&#160;</p>
<p style="position:absolute;top:349px;left:90px;white-space:nowrap" class="ft94">important. This is illustrated by the comparison made in Table 2.2,&#160;</p>
<p style="position:absolute;top:367px;left:90px;white-space:nowrap" class="ft94">showing&#160;that&#160;many&#160;more&#160;extra&#160;cases&#160;will&#160;occur&#160;in&#160;the&#160;situation&#160;where&#160;</p>
<p style="position:absolute;top:385px;left:90px;white-space:nowrap" class="ft94">the baseline risk is high.</p>
<p style="position:absolute;top:403px;left:103px;white-space:nowrap" class="ft94">The fundamental problem with measuring safety is that it is much&#160;</p>
<p style="position:absolute;top:421px;left:90px;white-space:nowrap" class="ft94">more difficult to determine that an effect is absent than to measure&#160;</p>
<p style="position:absolute;top:439px;left:90px;white-space:nowrap" class="ft94">one that is present. We may be hoping or expecting to observe no&#160;</p>
<p style="position:absolute;top:457px;left:90px;white-space:nowrap" class="ft94">effect but if nothing goes wrong, does that mean everything is&#160;</p>
<p style="position:absolute;top:475px;left:90px;white-space:nowrap" class="ft94">all right?</p>
<p style="position:absolute;top:493px;left:103px;white-space:nowrap" class="ft94">The&#160;<i>rule of three</i>&#160;is a simple and useful tool when zero cases have&#160;</p>
<p style="position:absolute;top:511px;left:90px;white-space:nowrap" class="ft94">been observed in a defined population (NB it cannot be used if any&#160;</p>
<p style="position:absolute;top:529px;left:90px;white-space:nowrap" class="ft94">cases have occurred). Simply dividing the size of population by 3&#160;</p>
<p style="position:absolute;top:547px;left:90px;white-space:nowrap" class="ft94">approximates an upper 95% confidence limit. In practice, this is the&#160;</p>
<p style="position:absolute;top:565px;left:90px;white-space:nowrap" class="ft94">highest value that, statistically, is reasonably likely to represent the&#160;</p>
<p style="position:absolute;top:583px;left:90px;white-space:nowrap" class="ft94">truth. For example, if 900 patients use a new antibiotic and 0 allergic&#160;</p>
<p style="position:absolute;top:601px;left:90px;white-space:nowrap" class="ft94">reactions occur, then it is statistically unlikely that such reactions will&#160;</p>
<p style="position:absolute;top:619px;left:90px;white-space:nowrap" class="ft94">occur more frequently than 1 in 300 patients (i.e. 1 in 900/3).</p>
<p style="position:absolute;top:637px;left:103px;white-space:nowrap" class="ft94">The rule of three works very well provided the size of the population is&#160;</p>
<p style="position:absolute;top:655px;left:90px;white-space:nowrap" class="ft94">at least 30 and thus, in the context of drug safety, it usually is applicable.</p>
<p style="position:absolute;top:694px;left:90px;white-space:nowrap" class="ft91"><b>Table 2.2&#160;</b></p>
<p style="position:absolute;top:695px;left:145px;white-space:nowrap" class="ft96">Comparison between the number of extra cases produced by differing&#160;</p>
<p style="position:absolute;top:710px;left:90px;white-space:nowrap" class="ft96">relative risks according to the level of baseline risk.</p>
<p style="position:absolute;top:747px;left:96px;white-space:nowrap" class="ft97"><b>Baseline risk</b></p>
<p style="position:absolute;top:747px;left:263px;white-space:nowrap" class="ft97"><b>Relative risk</b></p>
<p style="position:absolute;top:747px;left:401px;white-space:nowrap" class="ft97"><b>Extra cases per million</b></p>
<p style="position:absolute;top:779px;left:96px;white-space:nowrap" class="ft96">1 in 100 (common)</p>
<p style="position:absolute;top:779px;left:263px;white-space:nowrap" class="ft96">1.1 (small increase)</p>
<p style="position:absolute;top:779px;left:401px;white-space:nowrap" class="ft96">1000</p>
<p style="position:absolute;top:800px;left:96px;white-space:nowrap" class="ft96">1 in 1&#160;000&#160;000 (very rare)</p>
<p style="position:absolute;top:800px;left:263px;white-space:nowrap" class="ft96">10 (large increase)</p>
<p style="position:absolute;top:800px;left:401px;white-space:nowrap" class="ft96">10</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title></title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft100{font-size:10px;font-family:Times;color:#4291c5;}
	.ft101{font-size:10px;font-family:Times;color:#4291c5;}
	.ft102{font-size:11px;font-family:Times;color:#8dbddc;}
	.ft103{font-size:13px;font-family:Times;color:#000000;}
	.ft104{font-size:5px;font-family:Times;color:#4291c5;}
	.ft105{font-size:13px;font-family:Times;color:#000000;}
	.ft106{font-size:13px;font-family:Times;color:#000000;}
	.ft107{font-size:13px;font-family:Times;color:#4291c5;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page10-div" style="position:relative;width:595px;height:918px;">
<img width="595" height="918" src="target010.png" alt="background image"/>
<p style="position:absolute;top:73px;left:73px;white-space:nowrap" class="ft100"><i>An Introduction to Pharmacovigilance</i></p>
<p style="position:absolute;top:73px;left:46px;white-space:nowrap" class="ft101"><b>28</b></p>
<p style="position:absolute;top:106px;left:73px;white-space:nowrap" class="ft102"><b>Safety in Practice</b></p>
<p style="position:absolute;top:132px;left:73px;white-space:nowrap" class="ft103">There are two basic components to safety:</p>
<p style="position:absolute;top:167px;left:79px;white-space:nowrap" class="ft104">&#160;</p>
<p style="position:absolute;top:167px;left:73px;white-space:nowrap" class="ft104">●</p>
<p style="position:absolute;top:159px;left:87px;white-space:nowrap" class="ft105"><i>Intrinsic safety</i>&#160;<b>–</b>&#160;some drugs&#160;are&#160;intrinsically and&#160;obviously safer&#160;</p>
<p style="position:absolute;top:177px;left:87px;white-space:nowrap" class="ft103">than others at therapeutic doses. For example, the adverse reactions&#160;</p>
<p style="position:absolute;top:195px;left:87px;white-space:nowrap" class="ft103">produced by paracetamol compared with cytotoxic drugs.</p>
<p style="position:absolute;top:221px;left:79px;white-space:nowrap" class="ft104">&#160;</p>
<p style="position:absolute;top:221px;left:73px;white-space:nowrap" class="ft104">●</p>
<p style="position:absolute;top:213px;left:87px;white-space:nowrap" class="ft105"><i>User‐dependent safety</i>&#160;<b>–</b>&#160;the safety of a drug can also depend on how&#160;</p>
<p style="position:absolute;top:231px;left:87px;white-space:nowrap" class="ft103">it is used. For example, monitoring white blood cell count in users&#160;</p>
<p style="position:absolute;top:249px;left:87px;white-space:nowrap" class="ft103">of clozapine can completely prevent reduction in white blood cells&#160;</p>
<p style="position:absolute;top:267px;left:87px;white-space:nowrap" class="ft103">to a level that would potentially have fatal consequences. Using&#160;</p>
<p style="position:absolute;top:285px;left:87px;white-space:nowrap" class="ft103">the drug without such monitoring is therefore clearly less safe than&#160;</p>
<p style="position:absolute;top:303px;left:87px;white-space:nowrap" class="ft103">following the recommended procedure. Another example of safety&#160;</p>
<p style="position:absolute;top:321px;left:87px;white-space:nowrap" class="ft103">being&#160;user‐dependent&#160;would&#160;be&#160;giving&#160;penicillin&#160;to&#160;someone&#160;who&#160;is&#160;</p>
<p style="position:absolute;top:339px;left:87px;white-space:nowrap" class="ft103">allergic to it, perhaps because that information has been ignored or&#160;</p>
<p style="position:absolute;top:357px;left:87px;white-space:nowrap" class="ft103">is not available. In such a case, the safeguard (i.e. means of minimis-</p>
<p style="position:absolute;top:375px;left:87px;white-space:nowrap" class="ft103">ing&#160;the&#160;risk)&#160;is&#160;avoidance&#160;of&#160;a&#160;specific&#160;drug&#160;in&#160;a&#160;particular&#160;individual.&#160;</p>
<p style="position:absolute;top:393px;left:87px;white-space:nowrap" class="ft103">Using an appropriate dose of medicine is an example of practising&#160;</p>
<p style="position:absolute;top:411px;left:87px;white-space:nowrap" class="ft103">risk minimisation that applies to most therapeutic situations.</p>
<p style="position:absolute;top:438px;left:86px;white-space:nowrap" class="ft103">The amount of safety knowledge available for a drug depends on&#160;</p>
<p style="position:absolute;top:456px;left:73px;white-space:nowrap" class="ft103">how&#160;much&#160;it&#160;has&#160;been&#160;studied&#160;and&#160;used.&#160;Broadly,&#160;there&#160;are&#160;four&#160;cate-</p>
<p style="position:absolute;top:474px;left:73px;white-space:nowrap" class="ft103">gories of safety in respect of the amount of knowledge available:</p>
<p style="position:absolute;top:501px;left:73px;white-space:nowrap" class="ft107">1)&#160;</p>
<p style="position:absolute;top:501px;left:92px;white-space:nowrap" class="ft105"><i>Well‐established</i>&#160;&#160;<b>–</b>&#160;drugs that have been widely used for many&#160;</p>
<p style="position:absolute;top:519px;left:92px;white-space:nowrap" class="ft103">(~ 20+) years for which it is unlikely that&#160;<i>completely unidentified</i>&#160;</p>
<p style="position:absolute;top:537px;left:92px;white-space:nowrap" class="ft103">safety issues will emerge.</p>
<p style="position:absolute;top:555px;left:73px;white-space:nowrap" class="ft107">2)&#160;</p>
<p style="position:absolute;top:555px;left:92px;white-space:nowrap" class="ft105"><i>Established&#160;–</i>&#160;drugs&#160;for&#160;which&#160;there&#160;is&#160;a&#160;substantial&#160;body&#160;of&#160;evi-</p>
<p style="position:absolute;top:573px;left:92px;white-space:nowrap" class="ft103">dence of safety in clinical use but not enough to meet level 1.</p>
<p style="position:absolute;top:591px;left:73px;white-space:nowrap" class="ft107">3)&#160;</p>
<p style="position:absolute;top:591px;left:92px;white-space:nowrap" class="ft105"><i>Provisional</i>&#160;<b>–</b>&#160;all newly authorised drugs until they have been used&#160;</p>
<p style="position:absolute;top:609px;left:92px;white-space:nowrap" class="ft103">fairly extensively in ordinary practice over a period of at least&#160;</p>
<p style="position:absolute;top:627px;left:92px;white-space:nowrap" class="ft103">5 years. During this period such drugs are normally under&#160;<i>addi-</i></p>
<p style="position:absolute;top:645px;left:92px;white-space:nowrap" class="ft105"><i>tional monitoring</i>&#160;(see Glossary) and their safety in ordinary prac-</p>
<p style="position:absolute;top:663px;left:92px;white-space:nowrap" class="ft103">tice needs to be studied proactively.</p>
<p style="position:absolute;top:681px;left:73px;white-space:nowrap" class="ft107">4)&#160;</p>
<p style="position:absolute;top:681px;left:92px;white-space:nowrap" class="ft105"><i>Limited</i>&#160;&#160;<b>–</b>&#160;all investigational drugs and the following situations&#160;</p>
<p style="position:absolute;top:699px;left:92px;white-space:nowrap" class="ft103">where the drug might be authorised on limited safety information:</p>
<p style="position:absolute;top:725px;left:98px;white-space:nowrap" class="ft104">&#160;</p>
<p style="position:absolute;top:725px;left:92px;white-space:nowrap" class="ft104">●</p>
<p style="position:absolute;top:717px;left:106px;white-space:nowrap" class="ft103">Small populations eligible for treatment (e.g. rare diseases, treat-</p>
<p style="position:absolute;top:735px;left:106px;white-space:nowrap" class="ft103">ments for which are known as&#160;<i>orphan drugs</i>). An example is&#160;</p>
<p style="position:absolute;top:753px;left:106px;white-space:nowrap" class="ft103">Gaucher’s disease, a lysosomal storage disorder, which is usually&#160;</p>
<p style="position:absolute;top:771px;left:106px;white-space:nowrap" class="ft103">treated with a recombinant glucocerebrosidase.</p>
<p style="position:absolute;top:797px;left:98px;white-space:nowrap" class="ft104">&#160;</p>
<p style="position:absolute;top:797px;left:92px;white-space:nowrap" class="ft104">●</p>
<p style="position:absolute;top:789px;left:106px;white-space:nowrap" class="ft103">Drugs with important benefits or where there is great clinical&#160;</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft103">need (i.e. situations where potentially large risks might be&#160;</p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft103">&#160;acceptable, such as in advanced cancer).</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title></title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft110{font-size:10px;font-family:Times;color:#4291c5;}
	.ft111{font-size:10px;font-family:Times;color:#4291c5;}
	.ft112{font-size:13px;font-family:Times;color:#000000;}
	.ft113{font-size:13px;font-family:Times;color:#000000;}
	.ft114{font-size:11px;font-family:Times;color:#8dbddc;}
	.ft115{font-size:5px;font-family:Times;color:#4291c5;}
	.ft116{font-size:13px;font-family:Times;color:#4291c5;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page11-div" style="position:relative;width:595px;height:918px;">
<img width="595" height="918" src="target011.png" alt="background image"/>
<p style="position:absolute;top:73px;left:451px;white-space:nowrap" class="ft110"><i>Basic Concepts&#160;</i><b>29</b></p>
<p style="position:absolute;top:106px;left:103px;white-space:nowrap" class="ft112">A logical principle following from this categorisation is that&#160;<i>all</i>&#160;use&#160;</p>
<p style="position:absolute;top:124px;left:90px;white-space:nowrap" class="ft112">of drugs in category 4 should be associated with systematic collection&#160;</p>
<p style="position:absolute;top:142px;left:90px;white-space:nowrap" class="ft112">of safety information.</p>
<p style="position:absolute;top:160px;left:103px;white-space:nowrap" class="ft112">It is important to recognise that drugs in the well‐established&#160;</p>
<p style="position:absolute;top:178px;left:90px;white-space:nowrap" class="ft112">&#160;category are not necessarily safer than those in lower categories (and&#160;</p>
<p style="position:absolute;top:196px;left:90px;white-space:nowrap" class="ft112">so on), only that more information is available about their safety.</p>
<p style="position:absolute;top:240px;left:90px;white-space:nowrap" class="ft114"><b>Risk–Benefit Balance</b></p>
<p style="position:absolute;top:266px;left:90px;white-space:nowrap" class="ft112">As absolute safety is an unattainable goal, the aim is to use medicines&#160;</p>
<p style="position:absolute;top:284px;left:90px;white-space:nowrap" class="ft112">with an&#160;<i>acceptable level of safety</i>. Various factors need to be consid-</p>
<p style="position:absolute;top:302px;left:90px;white-space:nowrap" class="ft112">ered in judging whether safety is or is not acceptable:</p>
<p style="position:absolute;top:337px;left:96px;white-space:nowrap" class="ft115">&#160;</p>
<p style="position:absolute;top:337px;left:90px;white-space:nowrap" class="ft115">●</p>
<p style="position:absolute;top:329px;left:103px;white-space:nowrap" class="ft112">The level of&#160;<i>absolute</i>&#160;risk(s) and the potential health consequences.</p>
<p style="position:absolute;top:355px;left:96px;white-space:nowrap" class="ft115">&#160;</p>
<p style="position:absolute;top:355px;left:90px;white-space:nowrap" class="ft115">●</p>
<p style="position:absolute;top:347px;left:103px;white-space:nowrap" class="ft112">The benefit(s) expected, also measured in absolute terms.</p>
<p style="position:absolute;top:373px;left:96px;white-space:nowrap" class="ft115">&#160;</p>
<p style="position:absolute;top:373px;left:90px;white-space:nowrap" class="ft115">●</p>
<p style="position:absolute;top:365px;left:103px;white-space:nowrap" class="ft112">The seriousness of the disease for which treatment is given.</p>
<p style="position:absolute;top:391px;left:96px;white-space:nowrap" class="ft115">&#160;</p>
<p style="position:absolute;top:391px;left:90px;white-space:nowrap" class="ft115">●</p>
<p style="position:absolute;top:383px;left:103px;white-space:nowrap" class="ft112">The risks and benefits of alternative approaches.</p>
<p style="position:absolute;top:409px;left:96px;white-space:nowrap" class="ft115">&#160;</p>
<p style="position:absolute;top:409px;left:90px;white-space:nowrap" class="ft115">●</p>
<p style="position:absolute;top:401px;left:103px;white-space:nowrap" class="ft112">The perspective and circumstances of the individual who is to be&#160;</p>
<p style="position:absolute;top:419px;left:103px;white-space:nowrap" class="ft112">exposed.</p>
<p style="position:absolute;top:446px;left:103px;white-space:nowrap" class="ft112">In&#160;practice,&#160;therefore,&#160;whether&#160;safety&#160;is&#160;acceptable&#160;cannot&#160;be&#160;</p>
<p style="position:absolute;top:464px;left:90px;white-space:nowrap" class="ft112">divorced from efficacy and expected benefits. The harms and benefits&#160;</p>
<p style="position:absolute;top:482px;left:90px;white-space:nowrap" class="ft112">of a medicine are balanced at two levels:</p>
<p style="position:absolute;top:509px;left:90px;white-space:nowrap" class="ft116">1)&#160;</p>
<p style="position:absolute;top:509px;left:109px;white-space:nowrap" class="ft113"><i>Population&#160;level</i> – this is&#160;a regulatory&#160;and research‐based task and&#160;</p>
<p style="position:absolute;top:527px;left:109px;white-space:nowrap" class="ft112">a&#160;question&#160;of&#160;whether,&#160;overall,&#160;the&#160;benefits&#160;that&#160;will&#160;accrue&#160;from&#160;</p>
<p style="position:absolute;top:545px;left:109px;white-space:nowrap" class="ft112">availability of a medicine will exceed the expected harms.</p>
<p style="position:absolute;top:563px;left:90px;white-space:nowrap" class="ft116">2)&#160;</p>
<p style="position:absolute;top:563px;left:109px;white-space:nowrap" class="ft113"><i>Individual level</i> – this is made by the clinician in consultation with&#160;</p>
<p style="position:absolute;top:581px;left:109px;white-space:nowrap" class="ft112">the patient and takes into account factors such as the patient’s pre-</p>
<p style="position:absolute;top:599px;left:109px;white-space:nowrap" class="ft112">vious treatment, disease severity and the patient’s circumstances&#160;</p>
<p style="position:absolute;top:617px;left:109px;white-space:nowrap" class="ft112">and preferences.</p>
<p style="position:absolute;top:644px;left:103px;white-space:nowrap" class="ft112">The&#160;process&#160;of balancing&#160;harms&#160;and&#160;benefits is&#160;a&#160;judgemental&#160;one&#160;</p>
<p style="position:absolute;top:662px;left:90px;white-space:nowrap" class="ft112">and an element of judgement is always likely to remain, despite&#160;</p>
<p style="position:absolute;top:680px;left:90px;white-space:nowrap" class="ft112">promising attempts that have been made to develop mathematical&#160;</p>
<p style="position:absolute;top:698px;left:90px;white-space:nowrap" class="ft112">tools to aid the process at the population level. The term risk–&#160;benefit&#160;</p>
<p style="position:absolute;top:716px;left:90px;white-space:nowrap" class="ft112">ratio has often been used but is best avoided. A ratio implies one&#160;</p>
<p style="position:absolute;top:734px;left:90px;white-space:nowrap" class="ft112">number divided by another and even if two simple numbers were&#160;</p>
<p style="position:absolute;top:752px;left:90px;white-space:nowrap" class="ft112">available to summarise risks and benefits, what would a ratio of, say,&#160;</p>
<p style="position:absolute;top:770px;left:90px;white-space:nowrap" class="ft112">1.5 mean? Conceptually it is preferable to use an additive process in&#160;</p>
<p style="position:absolute;top:788px;left:90px;white-space:nowrap" class="ft113"><i>risk–benefit assessment</i>&#160;and the resulting balance becomes analo-</p>
<p style="position:absolute;top:806px;left:90px;white-space:nowrap" class="ft112">gous to a financial balance, which is either positive or negative.&#160;</p>
<p style="position:absolute;top:824px;left:90px;white-space:nowrap" class="ft112">Ideally, a balance sheet &#160;would be constructed and the debits&#160;</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title></title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft120{font-size:10px;font-family:Times;color:#4291c5;}
	.ft121{font-size:10px;font-family:Times;color:#4291c5;}
	.ft122{font-size:13px;font-family:Times;color:#000000;}
	.ft123{font-size:11px;font-family:Times;color:#8dbddc;}
	.ft124{font-size:16px;font-family:Times;color:#4291c5;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page12-div" style="position:relative;width:595px;height:918px;">
<img width="595" height="918" src="target012.png" alt="background image"/>
<p style="position:absolute;top:73px;left:73px;white-space:nowrap" class="ft120"><i>An Introduction to Pharmacovigilance</i></p>
<p style="position:absolute;top:73px;left:46px;white-space:nowrap" class="ft121"><b>30</b></p>
<p style="position:absolute;top:106px;left:73px;white-space:nowrap" class="ft122">(i.e. &#160;the&#160;ADRs) would be&#160;&#160;subtracted from the credits (i.e. the&#160;</p>
<p style="position:absolute;top:124px;left:73px;white-space:nowrap" class="ft122">expected&#160;benefits),&#160;it&#160;is&#160;to&#160;be&#160;hoped&#160;leaving&#160;a&#160;positive&#160;balance.&#160;</p>
<p style="position:absolute;top:142px;left:73px;white-space:nowrap" class="ft122">The problems are that the credits and debits are not usually measur-</p>
<p style="position:absolute;top:160px;left:73px;white-space:nowrap" class="ft122">able in the same way and there is often uncertainty about the size of&#160;</p>
<p style="position:absolute;top:178px;left:73px;white-space:nowrap" class="ft122">some of the entries. Nevertheless, such an analogy is helpful in&#160;</p>
<p style="position:absolute;top:196px;left:73px;white-space:nowrap" class="ft122">assessing whether to&#160;achieve these&#160;&#160;benefits it is reasonable&#160;(or not)&#160;</p>
<p style="position:absolute;top:214px;left:73px;white-space:nowrap" class="ft122">to accept these risks of harm.</p>
<p style="position:absolute;top:257px;left:73px;white-space:nowrap" class="ft123"><b>Lack of Benefit</b></p>
<p style="position:absolute;top:283px;left:73px;white-space:nowrap" class="ft122">The efficacy and effectiveness of drugs is not considered in any detail&#160;</p>
<p style="position:absolute;top:301px;left:73px;white-space:nowrap" class="ft122">in this book because pharmacovigilance is primarily about clinical&#160;</p>
<p style="position:absolute;top:319px;left:73px;white-space:nowrap" class="ft122">safety of medicines. However, the expected benefits of a drug are an&#160;</p>
<p style="position:absolute;top:337px;left:73px;white-space:nowrap" class="ft122">important factor when considering whether safety is acceptable, and&#160;</p>
<p style="position:absolute;top:355px;left:73px;white-space:nowrap" class="ft122">the overall balance of risks and benefits for at least one indication&#160;</p>
<p style="position:absolute;top:373px;left:73px;white-space:nowrap" class="ft122">must be considered positive if a drug is to remain on the market.&#160;</p>
<p style="position:absolute;top:391px;left:73px;white-space:nowrap" class="ft122">Conversely, when a drug is initially launched there must be evidence&#160;</p>
<p style="position:absolute;top:409px;left:73px;white-space:nowrap" class="ft122">of efficacy and potential benefit, but this does not mean that the drug&#160;</p>
<p style="position:absolute;top:427px;left:73px;white-space:nowrap" class="ft122">will be beneficial to all patients (many drugs do not work in surpris-</p>
<p style="position:absolute;top:445px;left:73px;white-space:nowrap" class="ft122">ingly high proportions of patients) or that its ‘real world’ level of effec-</p>
<p style="position:absolute;top:463px;left:73px;white-space:nowrap" class="ft122">tiveness will be sufficient for the risk–benefit balance to be considered&#160;</p>
<p style="position:absolute;top:481px;left:73px;white-space:nowrap" class="ft122">positive, or remain constant over time.</p>
<p style="position:absolute;top:499px;left:86px;white-space:nowrap" class="ft122">The development of resistance to antibiotics is a good example&#160;</p>
<p style="position:absolute;top:517px;left:73px;white-space:nowrap" class="ft122">of diminishing effectiveness. If there is no longer any expectation of&#160;</p>
<p style="position:absolute;top:535px;left:73px;white-space:nowrap" class="ft122">&#160;benefit, then there can be no level of safety that will lead to a positive&#160;</p>
<p style="position:absolute;top:553px;left:73px;white-space:nowrap" class="ft122">risk–benefit balance. At the individual level, lack of efficacy can&#160;</p>
<p style="position:absolute;top:571px;left:73px;white-space:nowrap" class="ft122">sometimes be regarded as having serious safety implications (and&#160;</p>
<p style="position:absolute;top:589px;left:73px;white-space:nowrap" class="ft122">therefore potentially reportable as a suspected ADR), for example if&#160;</p>
<p style="position:absolute;top:607px;left:73px;white-space:nowrap" class="ft122">contraceptive products or devices fail, resulting in unintended&#160;</p>
<p style="position:absolute;top:625px;left:73px;white-space:nowrap" class="ft122">pregnancies.</p>
<p style="position:absolute;top:678px;left:73px;white-space:nowrap" class="ft124"><b>&#160;Causation – Was the Drug&#160;&#160;Responsible?</b></p>
<p style="position:absolute;top:718px;left:73px;white-space:nowrap" class="ft122">Deciding whether a drug is responsible for an AE is very often the most&#160;</p>
<p style="position:absolute;top:736px;left:73px;white-space:nowrap" class="ft122">important question facing scientists working in the field of pharma-</p>
<p style="position:absolute;top:754px;left:73px;white-space:nowrap" class="ft122">covigilance. Yet, it is rarely completely straightforward, whether the&#160;</p>
<p style="position:absolute;top:772px;left:73px;white-space:nowrap" class="ft122">&#160;matter is being considered at the level of an individual patient or in&#160;</p>
<p style="position:absolute;top:790px;left:73px;white-space:nowrap" class="ft122">terms of study data for various populations. As in the case of risk–&#160;</p>
<p style="position:absolute;top:808px;left:73px;white-space:nowrap" class="ft122">benefit assessment, a judgement is often necessary and there are&#160;</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title></title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft130{font-size:10px;font-family:Times;color:#4291c5;}
	.ft131{font-size:10px;font-family:Times;color:#4291c5;}
	.ft132{font-size:13px;font-family:Times;color:#000000;}
	.ft133{font-size:11px;font-family:Times;color:#8dbddc;}
	.ft134{font-size:13px;font-family:Times;color:#4291c5;}
	.ft135{font-size:13px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page13-div" style="position:relative;width:595px;height:918px;">
<img width="595" height="918" src="target013.png" alt="background image"/>
<p style="position:absolute;top:73px;left:451px;white-space:nowrap" class="ft130"><i>Basic Concepts&#160;</i><b>31</b></p>
<p style="position:absolute;top:106px;left:90px;white-space:nowrap" class="ft132">some&#160;&#160;principles to be applied. There are some similarities in approach&#160;</p>
<p style="position:absolute;top:124px;left:90px;white-space:nowrap" class="ft132">between the two levels mentioned, although they are considered&#160;</p>
<p style="position:absolute;top:142px;left:90px;white-space:nowrap" class="ft132">&#160;separately&#160;&#160;here.</p>
<p style="position:absolute;top:179px;left:90px;white-space:nowrap" class="ft133"><b>Causality Assessment in Individual Cases</b></p>
<p style="position:absolute;top:205px;left:90px;white-space:nowrap" class="ft132">Many causality algorithms and categorisation systems have been&#160;</p>
<p style="position:absolute;top:223px;left:90px;white-space:nowrap" class="ft132">&#160;proposed&#160;but&#160;none&#160;has&#160;gained&#160;universal&#160;acceptance,&#160;and&#160;the&#160;value&#160;of&#160;</p>
<p style="position:absolute;top:241px;left:90px;white-space:nowrap" class="ft132">assessing this for each individual report of a suspected ADR has been&#160;</p>
<p style="position:absolute;top:259px;left:90px;white-space:nowrap" class="ft132">questioned.&#160;It&#160;may&#160;be&#160;more&#160;efficient&#160;to&#160;reserve&#160;such&#160;assessment&#160;for&#160;a&#160;</p>
<p style="position:absolute;top:277px;left:90px;white-space:nowrap" class="ft132">series of cases which might represent a new and/or important safety&#160;</p>
<p style="position:absolute;top:295px;left:90px;white-space:nowrap" class="ft132">issue.&#160;Systematic&#160;assessment of causality&#160;in individual cases occurring&#160;</p>
<p style="position:absolute;top:313px;left:90px;white-space:nowrap" class="ft132">in clinical trials is generally a weaker approach to assessing causality&#160;</p>
<p style="position:absolute;top:331px;left:90px;white-space:nowrap" class="ft132">than comparison of numerical counts. However, in post‐marketing&#160;</p>
<p style="position:absolute;top:349px;left:90px;white-space:nowrap" class="ft132">surveillance, and especially&#160;in prescription‐event&#160;monitoring (PEM)&#160;</p>
<p style="position:absolute;top:367px;left:90px;white-space:nowrap" class="ft132">studies (see Chapter 3), causality assessment of individual AEs can be&#160;</p>
<p style="position:absolute;top:385px;left:90px;white-space:nowrap" class="ft132">important in determining which may be related to the medicine and&#160;</p>
<p style="position:absolute;top:403px;left:90px;white-space:nowrap" class="ft132">which represent background clinical events.</p>
<p style="position:absolute;top:421px;left:103px;white-space:nowrap" class="ft132">When individual case causality assessment is to be performed, there&#160;</p>
<p style="position:absolute;top:439px;left:90px;white-space:nowrap" class="ft132">are usually four categories into which a case might be placed following&#160;</p>
<p style="position:absolute;top:457px;left:90px;white-space:nowrap" class="ft132">analysis of all available clinical information:</p>
<p style="position:absolute;top:484px;left:90px;white-space:nowrap" class="ft134">1)&#160;</p>
<p style="position:absolute;top:484px;left:109px;white-space:nowrap" class="ft135"><i>Probable</i> &#160;– &#160;the&#160;balance&#160;of&#160;information&#160;available&#160;supports&#160;causa-</p>
<p style="position:absolute;top:502px;left:109px;white-space:nowrap" class="ft132">tion. Usually, evidence of a ‘positive rechallenge’ (reoccurrence of&#160;</p>
<p style="position:absolute;top:520px;left:109px;white-space:nowrap" class="ft132">the AE on readministration of the same dose of the suspect medi-</p>
<p style="position:absolute;top:538px;left:109px;white-space:nowrap" class="ft132">cine) is required for this category.</p>
<p style="position:absolute;top:556px;left:90px;white-space:nowrap" class="ft134">2)&#160;</p>
<p style="position:absolute;top:556px;left:109px;white-space:nowrap" class="ft135"><i>Possible</i> &#160;– &#160;some of the available information is in favour of and&#160;</p>
<p style="position:absolute;top:574px;left:109px;white-space:nowrap" class="ft132">some against causation. For this category, usually evidence of a&#160;</p>
<p style="position:absolute;top:592px;left:109px;white-space:nowrap" class="ft132">‘positive dechallenge’ (resolution of the AE symptoms after stop-</p>
<p style="position:absolute;top:610px;left:109px;white-space:nowrap" class="ft132">ping the suspect medicine) is required.</p>
<p style="position:absolute;top:628px;left:90px;white-space:nowrap" class="ft134">3)&#160;</p>
<p style="position:absolute;top:628px;left:109px;white-space:nowrap" class="ft135"><i>Unlikely</i> – the balance of information available is against causation.&#160;</p>
<p style="position:absolute;top:646px;left:109px;white-space:nowrap" class="ft132">For example, it is more likely that other factors (e.g. the patient’s&#160;</p>
<p style="position:absolute;top:664px;left:109px;white-space:nowrap" class="ft132">condition) have caused the AE.</p>
<p style="position:absolute;top:682px;left:90px;white-space:nowrap" class="ft134">4)&#160;</p>
<p style="position:absolute;top:682px;left:109px;white-space:nowrap" class="ft135"><i>Unassessable</i> &#160;– &#160;a reasonable judgement cannot be made, often&#160;</p>
<p style="position:absolute;top:700px;left:109px;white-space:nowrap" class="ft132">because key information is missing.</p>
<p style="position:absolute;top:727px;left:103px;white-space:nowrap" class="ft132">In making such judgements there are four broad areas to consider:</p>
<p style="position:absolute;top:754px;left:90px;white-space:nowrap" class="ft134">1)&#160;</p>
<p style="position:absolute;top:754px;left:109px;white-space:nowrap" class="ft135"><i>Temporal relationships</i> – what was the time relationship between&#160;</p>
<p style="position:absolute;top:772px;left:109px;white-space:nowrap" class="ft132">starting treatment and the onset of the event. If treatment was&#160;</p>
<p style="position:absolute;top:790px;left:109px;white-space:nowrap" class="ft132">stopped (‘dechallenge’) or restarted (‘rechallenge’), did the event&#160;</p>
<p style="position:absolute;top:808px;left:109px;white-space:nowrap" class="ft132">abate and/or recur?</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title></title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft140{font-size:10px;font-family:Times;color:#4291c5;}
	.ft141{font-size:10px;font-family:Times;color:#4291c5;}
	.ft142{font-size:13px;font-family:Times;color:#4291c5;}
	.ft143{font-size:13px;font-family:Times;color:#000000;}
	.ft144{font-size:13px;font-family:Times;color:#000000;}
	.ft145{font-size:11px;font-family:Times;color:#8dbddc;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page14-div" style="position:relative;width:595px;height:918px;">
<img width="595" height="918" src="target014.png" alt="background image"/>
<p style="position:absolute;top:73px;left:73px;white-space:nowrap" class="ft140"><i>An Introduction to Pharmacovigilance</i></p>
<p style="position:absolute;top:73px;left:46px;white-space:nowrap" class="ft141"><b>32</b></p>
<p style="position:absolute;top:106px;left:73px;white-space:nowrap" class="ft142">2)&#160;</p>
<p style="position:absolute;top:106px;left:92px;white-space:nowrap" class="ft143"><i>Alternative causes</i> &#160;– &#160;are there concomitant diseases and&#160;other&#160;</p>
<p style="position:absolute;top:124px;left:92px;white-space:nowrap" class="ft144">medications or non‐drug exposures that could explain the event?</p>
<p style="position:absolute;top:142px;left:73px;white-space:nowrap" class="ft142">3)&#160;</p>
<p style="position:absolute;top:142px;left:92px;white-space:nowrap" class="ft143"><i>Nature of the event</i> – some clinical events are often caused by drugs&#160;</p>
<p style="position:absolute;top:160px;left:92px;white-space:nowrap" class="ft144">and&#160;immediately&#160;suggest&#160;a&#160;relationship&#160;(e.g.&#160;certain&#160;types&#160;of&#160;skin&#160;</p>
<p style="position:absolute;top:178px;left:92px;white-space:nowrap" class="ft144">reactions such as toxic epidermal necrolysis; see Chapter 7).</p>
<p style="position:absolute;top:196px;left:73px;white-space:nowrap" class="ft142">4)&#160;</p>
<p style="position:absolute;top:196px;left:92px;white-space:nowrap" class="ft143"><i>Plausibility</i> – is&#160;the&#160;reaction&#160;already&#160;recognised&#160;with&#160;this&#160;drug&#160;(or&#160;</p>
<p style="position:absolute;top:214px;left:92px;white-space:nowrap" class="ft144">similar drugs) or can a biological mechanism be postulated based&#160;</p>
<p style="position:absolute;top:232px;left:92px;white-space:nowrap" class="ft144">on the pharmacology of the drug?</p>
<p style="position:absolute;top:259px;left:86px;white-space:nowrap" class="ft144">In terms&#160;of temporal association,&#160;sometimes causation can be&#160;defi-</p>
<p style="position:absolute;top:277px;left:73px;white-space:nowrap" class="ft144">nitely excluded; for example, ADRs cannot start before the drug is&#160;</p>
<p style="position:absolute;top:295px;left:73px;white-space:nowrap" class="ft144">given (although drugs can worsen existing diseases). On the other&#160;</p>
<p style="position:absolute;top:313px;left:73px;white-space:nowrap" class="ft144">hand, a positive rechallenge in the absence of alternative causes is&#160;</p>
<p style="position:absolute;top:331px;left:73px;white-space:nowrap" class="ft144">&#160;generally considered to be strong evidence for causation. While most&#160;</p>
<p style="position:absolute;top:349px;left:73px;white-space:nowrap" class="ft144">ADRs start early on in treatment this is not invariably true, as reflected&#160;</p>
<p style="position:absolute;top:367px;left:73px;white-space:nowrap" class="ft144">in the time course element of the DoTS classification already&#160;</p>
<p style="position:absolute;top:385px;left:73px;white-space:nowrap" class="ft144">discussed.</p>
<p style="position:absolute;top:403px;left:86px;white-space:nowrap" class="ft144">Merely because an alternative cause can be identified does not mean&#160;</p>
<p style="position:absolute;top:421px;left:73px;white-space:nowrap" class="ft144">that it was responsible.&#160;Possible other&#160;causes are often called&#160;</p>
<p style="position:absolute;top:439px;left:73px;white-space:nowrap" class="ft144">‘&#160;confounding factors’ and when they are present, cases are said to&#160;</p>
<p style="position:absolute;top:457px;left:73px;white-space:nowrap" class="ft144">be ‘confounded’. This is rather loose use of the word (see Figure 2.1)&#160;</p>
<p style="position:absolute;top:475px;left:73px;white-space:nowrap" class="ft144">and best avoided.</p>
<p style="position:absolute;top:493px;left:86px;white-space:nowrap" class="ft144">The issues of nature of the event and plausibility need to be consid-</p>
<p style="position:absolute;top:511px;left:73px;white-space:nowrap" class="ft144">ered with some caution – these factors may add to the arguments for&#160;</p>
<p style="position:absolute;top:529px;left:73px;white-space:nowrap" class="ft144">causation, but a clinical event that is not normally known to be drug‐</p>
<p style="position:absolute;top:547px;left:73px;white-space:nowrap" class="ft144">related or the absence of any information supporting plausibility is not&#160;</p>
<p style="position:absolute;top:565px;left:73px;white-space:nowrap" class="ft144">strong evidence against it. Absence of evidence is not the same as&#160;</p>
<p style="position:absolute;top:583px;left:73px;white-space:nowrap" class="ft144">&#160;evidence of absence.</p>
<p style="position:absolute;top:620px;left:73px;white-space:nowrap" class="ft145"><b>Assessing Causality from Clinical&#160;Trial Data</b></p>
<p style="position:absolute;top:646px;left:73px;white-space:nowrap" class="ft144">One of the main reasons why data from randomised controlled trials&#160;</p>
<p style="position:absolute;top:664px;left:73px;white-space:nowrap" class="ft144">are considered to be the gold standard is that, in principle, observed&#160;</p>
<p style="position:absolute;top:682px;left:73px;white-space:nowrap" class="ft144">differences&#160;between&#160;randomised&#160;groups&#160;should&#160;be&#160;attributable&#160;to&#160;the&#160;</p>
<p style="position:absolute;top:700px;left:73px;white-space:nowrap" class="ft144">different treatments (i.e. causal). Other explanations are still possible,&#160;</p>
<p style="position:absolute;top:718px;left:73px;white-space:nowrap" class="ft144">for example differences could&#160;simply be&#160;due to chance or caused by&#160;</p>
<p style="position:absolute;top:736px;left:73px;white-space:nowrap" class="ft144">various&#160;biases,&#160;particularly&#160;in&#160;relation&#160;to&#160;what&#160;is&#160;being&#160;measured.&#160;</p>
<p style="position:absolute;top:754px;left:73px;white-space:nowrap" class="ft144">Problems with the randomisation may also occur – such as that it may&#160;</p>
<p style="position:absolute;top:772px;left:73px;white-space:nowrap" class="ft144">not have been carried out properly. Sometimes, as a result of bad luck,&#160;</p>
<p style="position:absolute;top:790px;left:73px;white-space:nowrap" class="ft144">randomisation may not have worked to produce groups that were&#160;</p>
<p style="position:absolute;top:808px;left:73px;white-space:nowrap" class="ft144">adequately&#160;balanced&#160;at&#160;baseline&#160;in&#160;terms&#160;of&#160;important&#160;factors&#160;that&#160;may&#160;</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title></title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft150{font-size:10px;font-family:Times;color:#4291c5;}
	.ft151{font-size:10px;font-family:Times;color:#4291c5;}
	.ft152{font-size:13px;font-family:Times;color:#000000;}
	.ft153{font-size:11px;font-family:Times;color:#8dbddc;}
	.ft154{font-size:13px;font-family:Times;color:#000000;}
	.ft155{font-size:11px;line-height:17px;font-family:Times;color:#8dbddc;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page15-div" style="position:relative;width:595px;height:918px;">
<img width="595" height="918" src="target015.png" alt="background image"/>
<p style="position:absolute;top:73px;left:451px;white-space:nowrap" class="ft150"><i>Basic Concepts&#160;</i><b>33</b></p>
<p style="position:absolute;top:106px;left:90px;white-space:nowrap" class="ft152">predict the outcome of interest. While all these&#160;alternative explana-</p>
<p style="position:absolute;top:124px;left:90px;white-space:nowrap" class="ft152">tions need to be considered, when a difference that looks important is&#160;</p>
<p style="position:absolute;top:142px;left:90px;white-space:nowrap" class="ft152">observed in a randomised trial, causation is the most likely explana-</p>
<p style="position:absolute;top:160px;left:90px;white-space:nowrap" class="ft152">tion. If the trial has adequate statistical power (and the observed dif-</p>
<p style="position:absolute;top:178px;left:90px;white-space:nowrap" class="ft152">ference is statistically&#160;significant),&#160;the groups&#160;were well‐balanced&#160;at&#160;</p>
<p style="position:absolute;top:196px;left:90px;white-space:nowrap" class="ft152">baseline and the measurements are objective or blinded, then no great&#160;</p>
<p style="position:absolute;top:214px;left:90px;white-space:nowrap" class="ft152">element of judgement is required to accept that such a difference&#160;</p>
<p style="position:absolute;top:232px;left:90px;white-space:nowrap" class="ft152">between treatments is likely to be real.</p>
<p style="position:absolute;top:278px;left:90px;white-space:nowrap" class="ft155"><b>Causality in Non‐Randomised Studies – The Problems of&#160;<br/>Bias and Confounding</b></p>
<p style="position:absolute;top:322px;left:90px;white-space:nowrap" class="ft152">For study data that are not randomised, assessing causation requires&#160;</p>
<p style="position:absolute;top:340px;left:90px;white-space:nowrap" class="ft152">much more judgement and is often a source of debate. When such&#160;</p>
<p style="position:absolute;top:358px;left:90px;white-space:nowrap" class="ft152">studies find a difference, this is known as an&#160;<i>association</i>. In terms of&#160;</p>
<p style="position:absolute;top:376px;left:90px;white-space:nowrap" class="ft152">chance, the issues are much the same as for randomised trials, but&#160;</p>
<p style="position:absolute;top:394px;left:90px;white-space:nowrap" class="ft152">there are many more types of biases that may be relevant. In the real&#160;</p>
<p style="position:absolute;top:412px;left:90px;white-space:nowrap" class="ft152">world, people tend to do things for a reason and patients who are&#160;</p>
<p style="position:absolute;top:430px;left:90px;white-space:nowrap" class="ft152">given particular treatments may be selected according to factors that&#160;</p>
<p style="position:absolute;top:448px;left:90px;white-space:nowrap" class="ft152">are relevant to the outcome of interest. For example, patients using&#160;</p>
<p style="position:absolute;top:466px;left:90px;white-space:nowrap" class="ft152">coxibs (see Chapter 1) are often selected on the basis of being at higher&#160;</p>
<p style="position:absolute;top:484px;left:90px;white-space:nowrap" class="ft152">baseline risk&#160;of gastrointestinal&#160;bleeding&#160;than&#160;patients&#160;using tradi-</p>
<p style="position:absolute;top:502px;left:90px;white-space:nowrap" class="ft152">tional anti‐inflammatory drugs. Non‐randomised comparative stud-</p>
<p style="position:absolute;top:520px;left:90px;white-space:nowrap" class="ft152">ies that did not address this bias would therefore be likely to (wrongly)&#160;</p>
<p style="position:absolute;top:538px;left:90px;white-space:nowrap" class="ft152">observe&#160;the&#160;opposite&#160;of&#160;what&#160;is&#160;found&#160;in&#160;trials.&#160;A&#160;further&#160;potential&#160;bias&#160;</p>
<p style="position:absolute;top:556px;left:90px;white-space:nowrap" class="ft152">is that losses to follow‐up are more likely than in trials and the reasons&#160;</p>
<p style="position:absolute;top:574px;left:90px;white-space:nowrap" class="ft152">why people are ‘lost’ from studies may not be random. For example,&#160;</p>
<p style="position:absolute;top:592px;left:90px;white-space:nowrap" class="ft152">patients could be lost from follow‐up because they have died from&#160;</p>
<p style="position:absolute;top:610px;left:90px;white-space:nowrap" class="ft152">an ADR.</p>
<p style="position:absolute;top:628px;left:103px;white-space:nowrap" class="ft152">Aside from the greater problem of bias, there is also the problem of&#160;</p>
<p style="position:absolute;top:646px;left:90px;white-space:nowrap" class="ft154"><i>confounding</i>&#160;in non‐randomised studies. A confounder has a triangu-</p>
<p style="position:absolute;top:664px;left:90px;white-space:nowrap" class="ft152">lar relationship with an exposure (usually a drug) and outcome (AE of&#160;</p>
<p style="position:absolute;top:682px;left:90px;white-space:nowrap" class="ft152">interest;&#160;&#160;Figure 2.1).&#160;When&#160;it&#160;is&#160;present,&#160;the&#160;risk&#160;of&#160;the&#160;outcome&#160;is&#160;</p>
<p style="position:absolute;top:700px;left:90px;white-space:nowrap" class="ft152">affected and whether or not it is present also varies according to the&#160;</p>
<p style="position:absolute;top:718px;left:90px;white-space:nowrap" class="ft152">exposure status. Age is a good example of a perennial confounder – in&#160;</p>
<p style="position:absolute;top:736px;left:90px;white-space:nowrap" class="ft152">very simple terms, older people tend to use more drugs and have more&#160;</p>
<p style="position:absolute;top:754px;left:90px;white-space:nowrap" class="ft152">adverse outcomes. Therefore there is a need to be sure that any&#160;</p>
<p style="position:absolute;top:772px;left:90px;white-space:nowrap" class="ft152">observed association is not simply a consequence of that. A ran-</p>
<p style="position:absolute;top:790px;left:90px;white-space:nowrap" class="ft152">domised study will, unless it is small, tend to balance the groups for&#160;</p>
<p style="position:absolute;top:808px;left:90px;white-space:nowrap" class="ft152">age – or indeed any confounder – largely circumventing this problem.&#160;</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title></title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft160{font-size:10px;font-family:Times;color:#4291c5;}
	.ft161{font-size:10px;font-family:Times;color:#4291c5;}
	.ft162{font-size:13px;font-family:Times;color:#000000;}
	.ft163{font-size:13px;font-family:Times;color:#000000;}
	.ft164{font-size:11px;font-family:Times;color:#8dbddc;}
	.ft165{font-size:5px;font-family:Times;color:#4291c5;}
	.ft166{font-size:10px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page16-div" style="position:relative;width:595px;height:918px;">
<img width="595" height="918" src="target016.png" alt="background image"/>
<p style="position:absolute;top:73px;left:73px;white-space:nowrap" class="ft160"><i>An Introduction to Pharmacovigilance</i></p>
<p style="position:absolute;top:73px;left:46px;white-space:nowrap" class="ft161"><b>34</b></p>
<p style="position:absolute;top:338px;left:73px;white-space:nowrap" class="ft162">In principle, confounding can be dealt with, either in the study design&#160;</p>
<p style="position:absolute;top:356px;left:73px;white-space:nowrap" class="ft162">(e.g. by matching patients or groups so that relevant factors are bal-</p>
<p style="position:absolute;top:374px;left:73px;white-space:nowrap" class="ft162">anced) or in the analysis by statistical adjustment. However, to do so&#160;</p>
<p style="position:absolute;top:392px;left:73px;white-space:nowrap" class="ft162">requires that all potential confounders are identified and adequately&#160;</p>
<p style="position:absolute;top:410px;left:73px;white-space:nowrap" class="ft162">measured. Smoking is another common confounder and knowledge&#160;</p>
<p style="position:absolute;top:428px;left:73px;white-space:nowrap" class="ft162">of smoking status in terms of (say) current, ex‐ or non‐smoker is fairly&#160;</p>
<p style="position:absolute;top:446px;left:73px;white-space:nowrap" class="ft162">crude given that there may be a close relationship between the precise&#160;</p>
<p style="position:absolute;top:464px;left:73px;white-space:nowrap" class="ft162">amount&#160;smoked&#160;and&#160;the&#160;risk of&#160;the&#160;outcome.&#160;The&#160;possibility&#160;that&#160;con-</p>
<p style="position:absolute;top:482px;left:73px;white-space:nowrap" class="ft162">founding has not been fully addressed is called&#160;<i>residual confounding</i>&#160;</p>
<p style="position:absolute;top:500px;left:73px;white-space:nowrap" class="ft162">and this is often a possible alternative explanation to causation when&#160;</p>
<p style="position:absolute;top:518px;left:73px;white-space:nowrap" class="ft162">data come from non‐randomised studies.</p>
<p style="position:absolute;top:555px;left:73px;white-space:nowrap" class="ft164"><b>Using the Bradford &#160;Hill Criteria to Assess Causality</b></p>
<p style="position:absolute;top:581px;left:73px;white-space:nowrap" class="ft162">When chance, bias and confounding are considered unlikely, causa-</p>
<p style="position:absolute;top:599px;left:73px;white-space:nowrap" class="ft162">tion is possible but still cannot be assumed as an explanation for an&#160;</p>
<p style="position:absolute;top:617px;left:73px;white-space:nowrap" class="ft162">association based on non‐randomised data. Often, there are a series of&#160;</p>
<p style="position:absolute;top:635px;left:73px;white-space:nowrap" class="ft162">studies or various types of data that bear on this question. In this con-</p>
<p style="position:absolute;top:653px;left:73px;white-space:nowrap" class="ft162">text, nine criteria first described by Bradford Hill in the 1960s are still&#160;</p>
<p style="position:absolute;top:671px;left:73px;white-space:nowrap" class="ft162">used. Five of these can be summarised as follows:</p>
<p style="position:absolute;top:706px;left:79px;white-space:nowrap" class="ft165">&#160;</p>
<p style="position:absolute;top:706px;left:73px;white-space:nowrap" class="ft165">●</p>
<p style="position:absolute;top:698px;left:87px;white-space:nowrap" class="ft163"><i>Strength</i> – the stronger an association is, the less likely it is to be&#160;</p>
<p style="position:absolute;top:716px;left:87px;white-space:nowrap" class="ft162">explained by other factors.</p>
<p style="position:absolute;top:742px;left:79px;white-space:nowrap" class="ft165">&#160;</p>
<p style="position:absolute;top:742px;left:73px;white-space:nowrap" class="ft165">●</p>
<p style="position:absolute;top:734px;left:87px;white-space:nowrap" class="ft163"><i>Consistency</i> &#160;– &#160;repeated observation of an association in different&#160;</p>
<p style="position:absolute;top:752px;left:87px;white-space:nowrap" class="ft162">studies and under different conditions support causation.</p>
<p style="position:absolute;top:778px;left:79px;white-space:nowrap" class="ft165">&#160;</p>
<p style="position:absolute;top:778px;left:73px;white-space:nowrap" class="ft165">●</p>
<p style="position:absolute;top:770px;left:87px;white-space:nowrap" class="ft163"><i>Specificity</i> – a few ADRs are completely unique syndromes (some&#160;</p>
<p style="position:absolute;top:788px;left:87px;white-space:nowrap" class="ft162">examples were given earlier) and their specificity means that&#160;</p>
<p style="position:absolute;top:806px;left:87px;white-space:nowrap" class="ft162">&#160;causation is hardly in doubt.</p>
<p style="position:absolute;top:114px;left:205px;white-space:nowrap" class="ft166">Confounder (e.g.&#160;age)</p>
<p style="position:absolute;top:216px;left:78px;white-space:nowrap" class="ft166">Exposure (e.g.&#160;drug)</p>
<p style="position:absolute;top:216px;left:339px;white-space:nowrap" class="ft166">Outcome (e.g.&#160;ADR)</p>
<p style="position:absolute;top:249px;left:73px;white-space:nowrap" class="ft161"><b>Figure 2.1&#160;</b></p>
<p style="position:absolute;top:249px;left:134px;white-space:nowrap" class="ft166">The triangular relationship between a confounder, an exposure and&#160;</p>
<p style="position:absolute;top:264px;left:73px;white-space:nowrap" class="ft166">an outcome. By influencing both the probability of being exposed and the&#160;</p>
<p style="position:absolute;top:279px;left:73px;white-space:nowrap" class="ft166">probability of the outcome occurring, a confounder distorts the relationship of&#160;</p>
<p style="position:absolute;top:294px;left:73px;white-space:nowrap" class="ft166">interest (i.e. between the exposure and outcome).</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title></title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft170{font-size:10px;font-family:Times;color:#4291c5;}
	.ft171{font-size:10px;font-family:Times;color:#4291c5;}
	.ft172{font-size:5px;font-family:Times;color:#4291c5;}
	.ft173{font-size:13px;font-family:Times;color:#000000;}
	.ft174{font-size:13px;font-family:Times;color:#000000;}
	.ft175{font-size:13px;font-family:Times;color:#000000;}
	.ft176{font-size:16px;font-family:Times;color:#4291c5;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page17-div" style="position:relative;width:595px;height:918px;">
<img width="595" height="918" src="target017.png" alt="background image"/>
<p style="position:absolute;top:73px;left:451px;white-space:nowrap" class="ft170"><i>Basic Concepts&#160;</i><b>35</b></p>
<p style="position:absolute;top:114px;left:96px;white-space:nowrap" class="ft172">&#160;</p>
<p style="position:absolute;top:114px;left:90px;white-space:nowrap" class="ft172">●</p>
<p style="position:absolute;top:106px;left:103px;white-space:nowrap" class="ft173"><i>Temporality</i>&#160;&#160;<b>–</b>&#160;exposure to the suspect medicine must precede&#160;</p>
<p style="position:absolute;top:124px;left:103px;white-space:nowrap" class="ft174">&#160;outcomes in a consistent manner.</p>
<p style="position:absolute;top:150px;left:96px;white-space:nowrap" class="ft172">&#160;</p>
<p style="position:absolute;top:150px;left:90px;white-space:nowrap" class="ft172">●</p>
<p style="position:absolute;top:142px;left:103px;white-space:nowrap" class="ft173"><i>Biological gradient</i>&#160;<b>–</b>&#160;is there evidence of dose‐ or duration‐related&#160;</p>
<p style="position:absolute;top:160px;left:103px;white-space:nowrap" class="ft174">risk?</p>
<p style="position:absolute;top:187px;left:103px;white-space:nowrap" class="ft174">The final four criteria are&#160;<i>plausibility, coherence, supportive experi-</i></p>
<p style="position:absolute;top:205px;left:90px;white-space:nowrap" class="ft173"><i>mental evidence</i>&#160;and&#160;<i>analogy</i>. These are related by a theme of whether&#160;</p>
<p style="position:absolute;top:223px;left:90px;white-space:nowrap" class="ft174">the association fits with existing scientific knowledge and beliefs. If so,&#160;</p>
<p style="position:absolute;top:241px;left:90px;white-space:nowrap" class="ft174">then causation is more likely but newly identified associations may&#160;</p>
<p style="position:absolute;top:259px;left:90px;white-space:nowrap" class="ft174">not fit, so absence of any (or all) of these criteria does not preclude an&#160;</p>
<p style="position:absolute;top:277px;left:90px;white-space:nowrap" class="ft174">association being causal.</p>
<p style="position:absolute;top:295px;left:103px;white-space:nowrap" class="ft174">In&#160;general&#160;terms,&#160;the&#160;more&#160;criteria&#160;that&#160;are&#160;met,&#160;the more likely&#160;an&#160;</p>
<p style="position:absolute;top:313px;left:90px;white-space:nowrap" class="ft174">association is to be causal. However, there is no simple formula for&#160;</p>
<p style="position:absolute;top:331px;left:90px;white-space:nowrap" class="ft174">adding up these criteria and coming to a definitive answer. Professional&#160;</p>
<p style="position:absolute;top:349px;left:90px;white-space:nowrap" class="ft174">judgement is required for such assessments and Bradford Hill’s&#160;&#160;criteria&#160;</p>
<p style="position:absolute;top:367px;left:90px;white-space:nowrap" class="ft174">are&#160;merely&#160;a&#160;conceptual&#160;framework&#160;for&#160;making&#160;such&#160;a&#160;judgement.&#160;It&#160;is&#160;</p>
<p style="position:absolute;top:385px;left:90px;white-space:nowrap" class="ft174">worth noting that some of the criteria (e.g. temporality, dose–response,&#160;</p>
<p style="position:absolute;top:403px;left:90px;white-space:nowrap" class="ft174">plausibility)&#160;are analogous to what was described for the assessment of&#160;</p>
<p style="position:absolute;top:421px;left:90px;white-space:nowrap" class="ft174">causality in individual cases.</p>
<p style="position:absolute;top:474px;left:90px;white-space:nowrap" class="ft176"><b>&#160;Conclusions</b></p>
<p style="position:absolute;top:514px;left:90px;white-space:nowrap" class="ft174">This chapter has considered the most fundamental concepts in phar-</p>
<p style="position:absolute;top:532px;left:90px;white-space:nowrap" class="ft174">macovigilance: what is an adverse effect of a medicine, how do we&#160;</p>
<p style="position:absolute;top:550px;left:90px;white-space:nowrap" class="ft174">know that&#160;it really&#160;is an&#160;adverse reaction, what&#160;is safety and on&#160;what&#160;</p>
<p style="position:absolute;top:568px;left:90px;white-space:nowrap" class="ft174">basis do we consider a treatment to be safe? We have discussed the&#160;</p>
<p style="position:absolute;top:586px;left:90px;white-space:nowrap" class="ft174">concept of measuring risk and the differences between relative and&#160;</p>
<p style="position:absolute;top:604px;left:90px;white-space:nowrap" class="ft174">absolute risk. The concept of the balance of risk and benefit is impor-</p>
<p style="position:absolute;top:622px;left:90px;white-space:nowrap" class="ft174">tant because a key goal of the pharmacovigilance process is to ensure&#160;</p>
<p style="position:absolute;top:640px;left:90px;white-space:nowrap" class="ft174">that the risks of drug treatments are outweighed by the benefits.&#160;</p>
<p style="position:absolute;top:658px;left:90px;white-space:nowrap" class="ft174">Finally, we have covered the concepts behind causality assessment, a&#160;</p>
<p style="position:absolute;top:676px;left:90px;white-space:nowrap" class="ft174">basic and vital tool in pharmacovigilance practice. The next step is to&#160;</p>
<p style="position:absolute;top:694px;left:90px;white-space:nowrap" class="ft174">consider in more detail the various kinds of data that help us to answer&#160;</p>
<p style="position:absolute;top:712px;left:90px;white-space:nowrap" class="ft174">such questions in relation to specific medicines and safety issues.</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title></title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft180{font-size:10px;font-family:Times;color:#4291c5;}
	.ft181{font-size:10px;font-family:Times;color:#000000;}
	.ft182{font-size:10px;font-family:Times;color:#000000;}
	.ft183{font-size:17px;font-family:Times;color:#4291c5;}
	.ft184{font-size:13px;font-family:Times;color:#000000;}
	.ft185{font-size:13px;font-family:Times;color:#4291c5;}
	.ft186{font-size:16px;font-family:Times;color:#4291c5;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page18-div" style="position:relative;width:595px;height:918px;">
<img width="595" height="918" src="target018.png" alt="background image"/>
<p style="position:absolute;top:73px;left:536px;white-space:nowrap" class="ft180"><b>37</b></p>
<p style="position:absolute;top:821px;left:90px;white-space:nowrap" class="ft181"><i>An Introduction to Pharmacovigilance</i>, Second Edition. Patrick Waller&#160;</p>
<p style="position:absolute;top:836px;left:90px;white-space:nowrap" class="ft182">and Mira Harrison-Woolrych.&#160;</p>
<p style="position:absolute;top:851px;left:90px;white-space:nowrap" class="ft182">© 2017 John Wiley &amp; Sons Ltd. Published 2017 by John Wiley &amp; Sons Ltd.</p>
<p style="position:absolute;top:223px;left:90px;white-space:nowrap" class="ft183"><b>3</b></p>
<p style="position:absolute;top:322px;left:90px;white-space:nowrap" class="ft184">The safety of medicines is under evaluation throughout the drug&#160;</p>
<p style="position:absolute;top:340px;left:90px;white-space:nowrap" class="ft184">development cycle. This process starts before humans are exposed,&#160;</p>
<p style="position:absolute;top:358px;left:90px;white-space:nowrap" class="ft184">and continues during the clinical development and post‐marketing&#160;</p>
<p style="position:absolute;top:376px;left:90px;white-space:nowrap" class="ft184">phases. Broadly, the safety of a medicine is tested in four phases, each&#160;</p>
<p style="position:absolute;top:394px;left:90px;white-space:nowrap" class="ft184">of which produces different types of data:</p>
<p style="position:absolute;top:421px;left:90px;white-space:nowrap" class="ft185">1)&#160;</p>
<p style="position:absolute;top:421px;left:109px;white-space:nowrap" class="ft184">Pre‐clinical (animal) studies</p>
<p style="position:absolute;top:439px;left:90px;white-space:nowrap" class="ft185">2)&#160;</p>
<p style="position:absolute;top:439px;left:109px;white-space:nowrap" class="ft184">Healthy human volunteer studies (Phase I)</p>
<p style="position:absolute;top:457px;left:90px;white-space:nowrap" class="ft185">3)&#160;</p>
<p style="position:absolute;top:457px;left:109px;white-space:nowrap" class="ft184">Clinical trials (Phases II and III)</p>
<p style="position:absolute;top:475px;left:90px;white-space:nowrap" class="ft185">4)&#160;</p>
<p style="position:absolute;top:475px;left:109px;white-space:nowrap" class="ft184">Post‐marketing surveillance (Phase IV)</p>
<p style="position:absolute;top:502px;left:103px;white-space:nowrap" class="ft184">Although there is a natural sequence defined by the above order, the&#160;</p>
<p style="position:absolute;top:520px;left:90px;white-space:nowrap" class="ft184">phases are not entirely distinct. Sometimes, new pre‐clinical studies&#160;</p>
<p style="position:absolute;top:538px;left:90px;white-space:nowrap" class="ft184">are&#160;undertaken for authorised products and,&#160;as we&#160;saw in&#160;Chapter 1,&#160;</p>
<p style="position:absolute;top:556px;left:90px;white-space:nowrap" class="ft184">clinical trials are increasingly becoming important post‐marketing.&#160;</p>
<p style="position:absolute;top:574px;left:90px;white-space:nowrap" class="ft184">Systematic reviews and meta‐analysis are important tools for bringing&#160;</p>
<p style="position:absolute;top:592px;left:90px;white-space:nowrap" class="ft184">together data from multiple studies. Although they have usually been&#160;</p>
<p style="position:absolute;top:610px;left:90px;white-space:nowrap" class="ft184">applied in the assessment of efficacy, their use for safety purposes is&#160;</p>
<p style="position:absolute;top:628px;left:90px;white-space:nowrap" class="ft184">increasing.</p>
<p style="position:absolute;top:681px;left:90px;white-space:nowrap" class="ft186"><b>&#160;Pre‐clinical&#160;&#160;Studies</b></p>
<p style="position:absolute;top:721px;left:90px;white-space:nowrap" class="ft184">Pre‐clinical studies are usually conducted in rodents (rabbit, mouse,&#160;</p>
<p style="position:absolute;top:739px;left:90px;white-space:nowrap" class="ft184">rat) and dogs or primates (monkeys). They aim to establish dosage&#160;</p>
<p style="position:absolute;top:757px;left:90px;white-space:nowrap" class="ft184">levels below which toxicity is not observed and to identify the organs&#160;</p>
<p style="position:absolute;top:263px;left:90px;white-space:nowrap" class="ft183"><b>Types and Sources of Data</b></p>
</div>
</body>
</html>
